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Depression is currently one of the leading causes worldwide of suicide and disability, the most 
common treatment is antidepressants. Most antidepressants work by increasing the monoamine 
levels in the central nervous system by inhibition of the reuptake of monoamines into the 
presynaptic neuron, and thereby ensure accumulation of the monoamines in the synaptic cleft. 
The main target for most antidepressants is the serotonin transporter, which is responsible for 
transporting serotonin, a monoamine, from the synaptic cleft back into the presynaptic neuron. 
The antidepressant (S)-citalopram is an antidepressant targeting the serotonin transporter that 
is well tolerated among patient populations. It is also the inhibitor that was rendered with best 
resolution in the recent crystal structures of the serotonin transporter. 
A computational study of the serotonin transporter with a focus on key amino acids for its 
function in both the central and allosteric sites using (S)-citalopram and its substrate serotonin 
as ligands in four MD simulations was performed. This shed light on some of the internal 
molecular mechanisms of the serotonin transporter, especially the interactions at the binding 
sites. Each simulation identified key amino acids between each respective ligand and binding 
site. For the central site simulation there was identified one key amino acid, TYR95, that both 
ligands had as their primary interaction and point of contact. There was also seen a disparity 
between (S)-citalopram and serotonin in terms of interaction types, with their preferences being 
hydrophobic and H-bonds respectively. For the allosteric site simulations, the interaction type 
trends were the same as for the central site. In the allosteric simulations the amino acids 
PHE335 and GLU494 were identified as the strongest interacting partners for (S)-citalopram 
and serotonin respectively. The interactions between the ligands and the allosteric site were 
also not as strong overall as the interactions of the central site. A docking study was also 
performed with verified inhibitors of the serotonin transporter that sought to investigate binding 
site interactions between the docked inhibitors and the protein. An overview of amino acid 
interactions was created, which allowed for the identification of amino acids that interacted 
with the vast majority of ligands docked into the respective binding sites. The data from the 
docking was also used to attempt to elucidate a connection between in silico and experimental 
results. 
In order for the study to involve experimental work an initial functional cAMP assay screening 
was incorporated into the project from an ongoing study in the research group. The assay tested 
10 compounds that had been identified through a virtual screening approach as being potential 
IV 
 
GABAB receptor antagonists. None of the 10 compounds showed antagonistic effects on the 
GABAB receptor, but there were indications that three of them may be agonists. Further assays 
are required to confirm the three compounds status as agonists. The experimental work 
provided experience working in a laboratory environment and carrying out every step of a 
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1.1 The Nervous System 
The nervous system plays a critical role in the human body and has a vital role in the body’s 
ability to maintain homeostasis. Communication of both the internal and external environment, 
as well as the coordination of corresponding activity between the widely disperse cells, tissues 
and organs that make up the human body is the primary function of the nervous system. A few 
examples of the many functions that the nervous system is responsible for managing within the 
body is the activation of muscle contraction, integrating respiratory system activity with the 
levels of blood oxygen, carbon dioxide and pH levels, as well as the modulation of the motility 
and secretions of the digestive system. Being one of two major control systems within the body, 
the other being the endocrine system with its relatively slow and long-lasting signals, the 
nervous system functions through the use of rapid electrical signals that travel through the body 
along the cellular membranes of nerve cells (1). 
The nervous system itself is divided into two parts, the Central Nervous System (CNS) and the 
Peripheral Nervous System (PNS). The CNS is made up of the brain and spinal cord, while the 
PNS is composed of the nerves connecting the brain and spinal cord to the tissues of the body. 
Both the CNS and the PNS are made up of the same basic unit, nerve cells, which are also 
called neurons (1). The structure of the neuron cells is itself highly polarized with distinct 
subcellular domains which help to promote a variety of functions. From a morphological 
standpoint, the typical neuron has three clearly definable regions; the cell body, the dendrites 
emanating from the cell body and the axon. The cell body itself, which is also known as the 
perikaryon, is where the nucleus and major cytoplasmic organelles are contained. The dendrites 
emanating from the cell body vary in number and the area they stretch across as well as their 
size and shape varies with the specific type of neuron. The dendrites act as signal receivers and 
accept signals from the axon terminals of other neuron cells. The axon, the last defined region 
of a neuron cell, conducts electrochemical and action potentials that the cell has received. It 
will in most cases stretch significantly further from the cell body than the emanating dendrites, 
it also emits a varying number of branches known as collateral axons. The axon and collateral 
axons have what is known as axon terminals at their end-points, which are used to send signals 
transmitted through the axon to the dendrites emanating from other neurons (2). The nervous 
system transmits information through these rapid electrical signals, which are generated by the 
neurons and used to communicate with either the same cell or neighboring cells. For most 
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neurons the response to receiving an electrical signal is the release of chemical messengers 
called neurotransmitters that serve as a means of communication with other cells (1, 2). 
There are numerous different neurotransmitters that act in the CNS and PNS, the exact number 
of these is not known, but it is known to more than 100. Although there is a significant degree 
of diversity among them it is still possible to classify them into two broad categories. The first 
of these categories is small-molecule neurotransmitters, which in general mediate rapid 
synaptic actions. The second category is neuropeptides, that most commonly modulate 
functions that are slower and ongoing. Despite the neurotransmitters being possible to 
categorize into two categories they all undergo a similar cycle of use (Figure 1). The first stage 
of this cycle is the synthesis of the neurotransmitter and its subsequent packaging into vesicles, 
all of which occurs in the presynaptic cell, the cell the signal originates from. The actual 
synthesis and packaging of the neurotransmitter varies somewhat between the small-molecule 
neurotransmitters, which are synthesized in the axon terminals, and the neuropeptides, which 
are synthesized in the cell body alongside enzymes that are needed to modify them before 
release. The neuropeptides are transported from the cell body through the axon before they are 
enzymatically modified in the axon terminals and subsequently released. The second stage 
involves the release of the neurotransmitter from the presynaptic cell and its subsequent binding 
to receptors on one or more postsynaptic cell, the postsynaptic cells are the receivers of the 
signal. The third and final stage is the rapid removal of the neurotransmitter and/or its 
degradation. This stage also has some variations between small-molecule neurotransmitters 
and neuropeptides. Small-molecule neurotransmitters either undergo reuptake directly or they 
are enzymatically degraded and their metabolites undergo reuptake. After this reuptake, they 
are ready to undergo another round of synthesis (only the metabolites), packaging, release and 
removal. Neuropeptides do not undergo reuptake, they instead diffuse away from the axon and 




Figure 1: The figure displays the process of synthesis and release, followed by reuptake or 
degradation for respectively neurotransmitters (left) and neuropeptides (right). There are also 
monoamine transporters that transport neurotransmitters back into the presynaptic neuron, 
these transporters are part of step 5 in the (left) figure and are not visualized in the figure. The 
figures has been modified from (3). 
 
These neurotransmitters serve a crucial role in the communication of the nervous system and 
abnormalities in their functionality are significant contributing factors to a wide range of both 
neurological and psychiatric disorders. Many therapeutic strategies aiming at treating such 
conditions therefore target various stages of a neurotransmitters functional life (3). 
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1.2 Neurological and Psychiatric Disorders 
Abnormalities related to neurotransmitters, such as abnormal regulation of their release or 
irregular extracellular concentration levels of the neurotransmitters, has a wide variety of 
impact upon an individual’s health. These abnormalities are the basis of hypotheses regarding 
the neuronal foundation of both behavioral and cognitive disorders. They are also considered 
symptomatic in the diagnosis of neuropsychiatric and neurodegenerative disorders. The 
abnormalities themselves are indications for that the ability of neurons to process information 
is being disrupted (4). This can cause, as evidenced by the many disorders such disruption is 
associated with, substantial health issues that are difficult to treat and the treatments often have 
numerous side-effects (5). 
 
1.2.1 Depression 
A common but serious disorder that is known to be related to abnormalities in neurotransmitter 
function is depression (6), also known as major depressive disorder and clinical depression. 
The symptoms of depression are wide and can vary significantly between patients, the degree 
of severity these symptoms exhibit also varies significantly. Core symptoms of a major 
depressive episode are having a «depressed mood» and the “loss of interest and pleasure in 
nearly all activities”, symptoms such as fatigue, anxiety and sleep disturbance are also quite 
common (7). The details are to this day not known regarding the underlying biological cause 
of depression. The hypothesis that has been dominant is that depression develops because of a 
low level of the monoamines, serotonin, dopamine (DA) and norepinephrine (NE), throughout 
certain areas of the CNS, and particularly in the limbic systems. The basis for this was that the 
first drugs with a therapeutic effect in depression acted by increasing the levels of these 
monoamines. It is not certain that the low levels of monoamines is the cause of depression, it 
is a possibility that it is a symptom of depression rather than a cause (8). 
Depression is sometimes characterized into two subtypes based on clinical symptoms displayed 
and rated on a scale based on the severity of the symptoms. The subtypes are melancholic 
depression and atypical depression, which historically were recommended different 
pharmacological treatments (7). Melancholic depression had tricyclic antidepressants (TCAs) 
and electroconvulsive therapy as the recommended treatment (9), while atypical depression 
had classical monoamine oxidase inhibitors (MAOIs) as the recommended treatment as 
patients with atypical depression seemed to respond better to MAOIs than tricyclic 
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antidepressants (10). The current generation of antidepressants have less of a distinction 
between them in regard to the treatment effectivity of depression subtypes, and there are 




All of this is indicative of the complexity and individual variation inherent in the disorder and 
by extension the complexity and variation of the abnormalities in neurotransmitter function. 
Despite this complexity and variation between patients there are numerous treatment options 
available for depression. These treatment options range from psychological therapy, 
electroconvulsive therapy and pharmacotherapy to a combination of those (11). The drug 
treatments affect the primary irregularities that are seen to play a major role in causing the 
symptoms of depression. These medications do not work for all patients with depression, and 
patients must often try numerous drugs before they find one that treats their symptoms. These 
medications also frequently cause a wide array of side effects (12).  
The current generation of antidepressants, such as the selective serotonin reuptake inhibitors 
(SSRIs), have a greater degree of selectivity than the previous generation, they also offer an 
improved level of safety of use and tolerability. The various TCAs and MAOIs among the first-
generation of antidepressants often possessed unwanted side-effects and also toxic effects in 
cases of overdoses, factors that limited their application in treatment to various degrees. 
Between the current generation antidepressants and the first-generation there is a common 
feature among all the antidepressants that remain on the market, they all increase the 
monoamine levels though by a variety of therapeutic mechanisms. Specifically they increase 
the levels DA, NE and/or serotonin (12). The improved selectivity of the newer generation 
allows the antidepressants to more narrowly affect the nervous system and thereby avoid some 







1.3 Targets for development of antidepressant drugs 
The CNS and PNS both have a significant variety in types of neurons that they are made up of, 
with there being about 100 distinct types of neurons possessing a wide variety of functions and 
morphologies. These distinct neuron types have all inherited the same gene complement, with 
their differences stemming from the restricted set of genes that they actively express. The 
restricted expression ensures only certain molecules are produced, be they enzymes, secretory 
products such as neurotransmitters, membrane constituents or structural proteins, while others 
are absent from that specific type of neuron. What makes one cell type unique compared to 
another is the specific set of molecules that it produces, the specific molecules enabling the cell 
to carry out its role (14).  
Of particular interest in the study of treatments for neurological and psychiatric disorders are 
the various membrane constituents, such as receptors and ion channels, and the various 
secretory products of neurons. These are the means by which a neuron communicates and 
disruption at this level of communications are theorized to be the cause or significant 
contributing factors to a large variety of disorders that afflict human beings of all ages (15). In 
modern drug development the receptors spread throughout the CNS and PNS are seen as 
critical targets in the treatment of many disorders, with some receptors standing out as of 
particular interest for certain diseases. Both the serotonin transporter (SERT) and the γ-
aminobutyric acid B (GABAB) receptor are among those standing out as of interest, with both 
proteins playing critical roles in the function of the nervous system (16, 17). 
 
1.3.1 Monoamine Transporters 
Located in the plasma membranes of monoaminergic neurons the monoamine transporters 
serve a crucial role in the regulation of a wide variety of bodily functions (18). They are highly 
significant transmembrane proteins, including among their numbers SERT, the dopamine 
transporter and the norepinephrine transporter (19). All of these proteins use ion gradients (Na+, 
Cl-) as their energy source for the transportation of their respective monoamines into or out of 
neurons. These transports play a critical regulatory role with their major function being the 
termination of monoamine transmission, which is accomplished by the removal of substrates 
from the synaptic cleft by inward transport into the presynaptic neuron (18). 
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There is also the vesicular monoamine transporters 1 and 2 (VMAT1 and VMAT2) located in 
the membrane of intracellular synaptic vesicles. These transporters make use of a proton 
gradient as their source of energy for sequestering cytosolic monoamines into vesicles which 
are subsequently released by exocytosis into the synaptic cleft (18). The VMAT transporters 
have been indicated by numerous studies to play a crucial role in the storage of, sorting and 
release of neurotransmitters. They have also been implicated in the fine-tuning of the 
informational output of both endocrine and neuronal sources (20-24). 
These transporters share an overall function in that they regulate the tempo-spatial components 
of monoamine transmission, and are in fact so crucial that the loss of even a single type of these 
transporters can cause severe diseases or even death (18). One example showcasing this in 
humans for the dopamine transporter would be that only two loss-of-function mutations, 
specifically L368Q and P395L, results in infantile parkinsonism-dystonia in humans (25). The 
monoamine transporters play a vital role in the human body, but they are also therefore a 
vulnerability. 
 
1.3.1.1 Solute Carrier Family 6 
The human genome contains 20 members of the solute carrier 6 (SLC6) family, these 20 
members are comprised of transporters of amino acids, energy metabolites, osmolytes and 
neurotransmitters. The members of the SLC6 family play crucial roles in neurotransmission as 
well as homeostasis at both the cellular and whole body level (26). The transporters in the 
family are secondary transporters that function by coupling the potential energy that is stored 
in preexisting ion gradients to enable them to transfer molecules across the cell membrane 
against the concentration gradient of the molecules. These transporters use a substrate 
translocation model known as the alternate access model, which entails the use of a central 
binding site that is connected to the intracellular and extracellular environments of the cell 
through the use of permeation pathways. As from the name, alternate access model, this type 
of transporter has its binding site only accessible to one permeation pathway at a time, which 
is accomplished by the transporter shifting conformations alternatively between the inward- 
and outward-facing conformations of the transporter (27, 28).   
The family, based on sequence similarity, can be subdivided into four branches (Figure 2); the 
monoamine transporter branch, γ-aminobutyric acid (GABA) transporter branch and the amino 




Figure 2: The figure displays a visualization of the sequence similarities of the human SLC6 
family transporters. T-coffee (29) was used to align all peptide sequences of the human SLC6 
members and the similarities were then visualized using the TreeView (30) application. The 
figure is modified from (26).  
 
Each of the different branches in the SLC6 family has a substrate preference that is different 
from the others. For the monoamine transporters branch the preferred substrates are serotonin, 
NE or DA. Each of these neurotransmitters have regulatory roles in the CNS and affect the 
activity of numerous pathways. Their regulation has a particularly prominent effect on mood, 
appetite, anxiety, attention, addiction, aggression, depression etc. (31, 32). The GABA 
transporter branch has transporters for GABA, creatine, betaine and taurine. GABA is of 
particular interest among these, being the major inhibitory neurotransmitter that affects the 
brain. Creatine has high-energy phosphate bonds that make it excellent at replenishing ATP, it 
is used as a storage compound for this purpose by primarily, but not exclusively, muscle tissue 
and the brain (33). Betaine and taurine both play a role in the regulation of the maintenance of 
cell volume and fluid balance through osmosis, both compounds fall within the group of 
compounds known as osmolytes. Then there are the amino acid transporter branches I and II. 
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The amino acid transporter branch I is made up of transporters for proline, glycine and also the 
general amino acid transporter ATB(0,+) (34, 35). The amino acid transporter branch II has 
amino acid transporters that are involved in the transport of amino acids in epithelial tissue and 
the brain (36). The majority of transporters in this branch are involved in amino acid 
homeostasis by virtue of their ability to accept a variety of neutral amino acids (26). 
 
1.3.1.2 The Serotonin Transporter 
One member of the SLC6 family is SERT, a monoamine transporter that plays a key role in the 
regulation of the serotonergic system. Specifically, it plays a role in terminating serotonergic 
neurotransmission by transporting serotonin into the presynaptic neuron from the synaptic cleft 
(Figure 3). Once in the presynaptic neuron the serotonin is either recycled into vesicles for 
storage or the cell converts it into an inactive metabolite (28). As it plays an important role in 
the serotonergic system, which is implicated in many physiological processes and behaviors as 
well as psychiatric disorders. It is considered an important target in the development of 




Figure 3: The figure displays the serotonin synapse. In the presynaptic neuron serotonin is 
synthesized by an enzyme named tryptophan hydroxylase from tryptophan. Once serotonin 
completes the subsequent packaging step, where it is packaged into vesicles, it is released into 
the synaptic cleft. The release into the synaptic cleft will only occur when the neuron has 
undergone sufficient stimulation. The serotonin that is released into the synaptic cleft from the 
presynaptic neuron has several actions it can undergo. 1) The serotonin binds to the appropriate 
receptors on the postsynaptic neuron, resulting in the signal that stimulated the presynaptic 
neuron being further transduced. 2) The serotonin binds to receptors on the presynaptic neuron, 
i.e. the neuron which released the serotonin, enabling feedback which in turn plays a role in 
regulating the neurons plasticity. 3) The serotonin undergoes reuptake by the presynaptic 
neuron through SERT, subsequently either being recycled for release in the future or broken 
down by the enzyme monoamine oxidase (40). The image is modified from an image by Lianne 
Friesen and Nicholas Woolridge.  
 
As with other members of the SLC6 family it is also a secondary transporter that uses a 
changing conformation, switching between inward- and outward-facing conformations, to 
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transport its substrate across the cell membrane against the concentration gradient. With these 
conformation shifts the binding site of SERT is only available from one side of the cell 
membrane at a time (27, 28). SERT gains the energy required for the transport of its substrate, 
serotonin, from an electrochemical gradient made up of sodium and chloride ions (41-44). In 
order for SERT to undergo the necessary changes to its conformation that are required for 
translocation all of its solutes are thought to be required to be bound in a 1:1:1 stoichiometry. 
The solutes required to bind for translocation are specifically serotonin, Na+ and Cl-, in addition 
there is an efflux of a single K+ ion that occurs separate from SERT itself (45, 46). 
For SERT the ions Na+ and Cl- also play a key role in the ability of inhibitors to bind to the 
protein. All known SERT inhibitors, with ibogaine being the only known exception, are 
stimulated to bind to SERT by Na+. Ibogaine is thought to be an exception to this because it is 
believed to stabilize an inward-facing conformation of SERT, the affinity of this inhibitor for 
SERT increases with the removal of Na+ (47-50). There are also several SERT inhibitors that 
are stimulated by Cl-, the most notable among these are citalopram, fluoxetine, imipramine and 
sertraline (48, 50).  
The structure of SERT has been the subject of study for many years (51, 52), but it is only in 
recent years that it was successfully crystalized (53). Having a crystal structure of SERT allows 
for the in silico study of the protein with a degree of accuracy that could not be achieved using 
only the amino acid sequence or a homology model (51, 54). The crystal structure that was 
rendered though X-ray crystallography is in the outward-open conformation (Figure 4), having 
the antidepressant drug (S)-citalopram bound to its orthosteric binding site, which is also often 
referred to as the central binding site. The central binding site of SERT is located halfway 
through the membrane in a cavity that is formed by residues from the transmembrane (TM) α-
helices 1, 3, 6, 8 and 10. Another rendering of the SERT crystal structure found that (S)-
citalopram was also bound to an allosteric site located in the extracellular vestibule that was 
approximately 13Å from the central site (53). The allosteric site of SERT has been shown to 
affect the inhibitory potential of (S)-citalopram, lowering the inhibitory potential if the 
allosteric site is disabled through mutation (55). SERT has a total of 12 TM helices that span 
the membrane, TMs 1 and 6 have short non- helical conformation regions in the area they skirt 
the central site for ligand binding. These short non- helical regions are contributors of residues 




Figure 4: The above figure displays the structure of SERT. A. The structure of SERT parallel 
to the membrane. B. The structure of SERT from the extracellular side of the membrane. (S)-
citalopram in the central and allosteric sites are shown as sticks, they are dark green and cyan 
in color respectively. The salmon colored spheres are Cl- ions (53). The numbered columns are 
the TM helices, EL refers to extracellular loops and IL refers to intracellular loops. The figure 
is modified from (53). 
 
SERT is the target of the antidepressant SSRI citalopram, which has been indicated as the best 
tolerated SSRI among patients (13). (S)-citalopram is the co-crystalized ligand for both the 
crystal structure with the best resolution (PDB ID 5I71, 3.15 Å) and also the crystal structure 
where the central and allosteric site was found to bind a ligand (PDB ID 5I73, 3,24 Å). 
 
1.3.2 G-Protein-Coupled Receptors 
A large group of proteins that is considered to contain numerous therapeutic targets of great 
potential for a wide spectrum of diseases are the G-protein-coupled receptors (GPCRs). This 
group of receptors is responsible for mediating the majority of physiological responses to 
neurotransmitters, hormones and environmental stimulants. The environmental stimulants that 
GPCRs are responsible for mediating are taste, olfaction and vision (56). There is also a 
significant variety and wide range to the ligands which may interact with GPCRs, included 
among these ligands are photons (light), ions, amino acids and large proteins (57). This large 
group of proteins play crucial rolls throughout the human body and defects or irregularities in 
many of the groups member proteins may lead to severe diseases (58). 
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When it comes to families of membrane proteins the GPCR family is the largest, with all 
members, at the most basic level, sharing several structural characteristics. The GPCRs all 
share the structural feature of having seven α-helical segments that span the cellular membrane, 
these segments are separated by loop regions that alternate between being intracellular and 
extracellular (56). This type of structural feature is called a heptahelical transmembrane 
domain, 7TM for short (59). 
The GPCRs in vertebrates can be divided into five families using the GRAFS classification 
system (60). The term GRAFS comes from the names of the families; Glutamate, Rhodopsin, 
Adhesion, Frizzled/Taste2, and Secretin. Of these families three of them, rhodopsin (Family 
A), secretin (Family B) and glutamate (Family C), correspond to an earlier GPCR classification 
system which split the GPCRs into a clan system going from A-F (61, 62). The adhesion and 
Frizzled/Taste2 families were not part of the GPCR clan system and were introduced with the 
GRAFS classification system (60). While the GPCR families do share similarities, there are 
significant differences between even individual GPCRs. Their signal-transduction activities are 
enabled through unique combinations of a multitude of G-protein subtypes, G-protein-
independent signaling pathways and the numerous complex processes with which they are 
regulated (56). Together this makes for a complex web of potential avenues for drugs to target 
in order to treat various diseases that occur as a consequence of these signal-transduction 
pathways being disrupted (58, 63). 
 
1.3.2.1 Family C receptors 
Among the GPCRs the Family C receptors, also known as the glutamate family of receptors, 
share the 7TM domain with the other GPCRs, but are distinguished by two structural features 
that are unique to the Family C receptors among the GPCRs. The first of these features is a 
large extracellular domain featuring a Venus flytrap (VFT) module as well as a cysteine rich 
domain (CRD). The VFT module contains the orthosteric sites of Family C receptors and the 
extracellular domain itself is situated away from the center of the 7TM helices. While the 7TM 
domain is a common feature among all GPCRs and is a conserved feature, it is noteworthy that 
the Family C receptors only possess allosteric sites in the 7TM domain. In the Family C 
receptors the majority of receptors contain a CRD, with only the GABAB receptor not 
containing one. The second of the features is that these GPCRs form constitutive dimers with 
modes of activation that are unique when compared with the other families of GPCRs. This 
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takes the form of homodimers for the metabotropic glutamate (mGlu) and Ca2+-sensing (Cas) 
receptors, while for the GABAB receptor and T1Rs it takes the form of heterodimers. This 
dimerization leads to an activation process that is particularly complex with allosteric 
interactions occurring between different dimer domains (57). 
In addition to the mGlu, Cas and GABAB receptors the Family C GPCRs are made up of 
pheromone receptors, amino acid and sweet taste receptors, odor receptors in fish and a few 
orphan receptors (59). The mGlu, Cas and GABAB receptors play critical roles in numerous 
disorders that may affect the CNS and calcium homeostasis, they are therefore considered 
therapeutic targets of great significance (64, 65). The taste receptors in the Family C receives 
a great deal of attention from the food industry, with many food companies being invested in 
taste additives which target these receptors (65). 
 
1.3.2.2 GABAB Receptor 
A member of the Family C of GPCRs that is of particular note in the study of numerous diseases 
and development of new pharmaceuticals is the GABAB receptor (17, 66, 67). It is one of three 
native receptors for GABA, the other two native receptors for GABA are the ionotropic 
GABAA and GABAC receptors. As GABA is the primary inhibitory neurotransmitter of the 
body there are many physiological functions that are regulated through GABA-mediated 
neurotransmission. Found in both pre- and postsynaptic inhibitory and excitatory synapses the 





Figure 5: The figure displays the structural organization of the GABAB receptor. The subunits 
that compose the heterodimer of the GABAB receptor, GABAB1a/b and GABAB2, can be seen 
in blue and red respectively. There are two variants of the GABAB1a/b subunit termed GABAB1a 
and GABAB1b. Binding of agonists and antagonists binding occur in the N-terminal VFT 
domain of the GABAB1a/b subunit. The figure is modified from (70). 
 
The GABAB receptor is as mentioned previously a heterodimer, which is made up of two 
subunits called GABAB1a/b and GABAB2 (Figure 5). Both these subunits are made up of three 
domains that are distinct from one another, the N-terminal extracellular VFT domain, the 7TM 
domain that all GPCRs possess and the intracellular C-terminal tail. There are two binding sites 
for ligands that have been identified in the GABAB receptor. The orthosteric binding site which 
is recognized by GABA, other agonists and antagonists is located in the VFT domain of the 
GABAB1a/b subunit, while an allosteric binding site is located in the 7TM of the GABAB2 








1.3.2.3 GABAB Receptor Signaling 
As the GABAB receptor is one of three receptors for GABA, the primary inhibitory 
neurotransmitter of the body, the signaling pathways that involve the GABAB receptor are 
complex and interconnected. The receptor is located both pre- and post-synaptically and is 
responsible for the regulation of synaptic transmission, which is accomplished through either 
inhibiting neurotransmitter release or the dampening of postsynaptic excitability (71). It is 
associated with a subset of G-proteins which themselves regulate specific ion channels or 
trigger or inhibit cyclic adenosine monophosphate (cAMP) cascades (72). Both presynaptic 
and postsynaptic activation leads to the G-protein mediated inhibition of adenylyl cyclase and 
thereby also a decrease in cAMP for the cell. Voltage gated calcium channels are also inhibited 
by both presynaptic and postsynaptic activation, with the presynaptic inhibition of the voltage 
gated calcium channels leading to a reduced release rate of GABA, serotonin, NE and DA (73). 
The complexity and multitude of the signaling pathways associated with the GABAB receptor 
is the reason why it is difficult to create a drug which only affects the GABAB receptor in one 
very specific manner with no side effects. The idea of creating a biased signaling drug, 
essentially a drug which would prefer one specific pathway available to a receptor, is of 
particular interest within drug discovery and development focused on proteins such as GPCRs 
with their multiple potential pathways (74). Biased signaling is therefore a focus of much 
research, also with the GABAB receptor, where it is hoped that biased signaling may provide 
the path to the development of an antidepressant targeting the GABAB receptor with less side 
effects than is possible with today’s drugs (75, 76). 
 
1.4 In silico methods in Drug Discovery and Development 
For new compounds to come to the market as antidepressants or other forms for medications it 
has to go through the process of drug discovery and development. This process has changed 
and evolved significantly over time, new technology allowing for new possibilities. From 
laboratory testing of compounds to determine their effects in the early stages of drug 
development to the current focused multi-step methodology that aims to bring highly selective 
and specific compounds to the market at a lower cost (77, 78). 
In the past compounds were discovered through trial and error in the laboratory and this process 
did indeed discover numerous compounds with effects worthy of clinical use, there was 
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however often numerous problematic side effects associated with these compounds. Over time 
related compounds were discovered that sometimes had less side effects, but these discoveries 
could take many years to arrive and many more to enter clinical settings (79). In the modern 
age with very steep costs of bringing a new compound to the market there have been developed 
numerous methods of evaluating a compounds efficiency as a pharmaceutical. What makes 
these methods different from those of the past is that many of them can be carried out in silico, 
removing the need to buy large libraries of compounds and testing them individually. 
Compounds can be evaluated in silico based on their ADMET (absorption, distribution, 
metabolism, excretion, toxicity) qualities, screening out any compounds that had qualities that 
would make them unfit to be used in marketable pharmaceuticals. The compounds can also be 
screened against both known ligands of the target protein to select ones with similar qualities 
and against the actual protein, docking the compound as a ligand into the protein to calculate 
how it would affect the protein. These methods, known as ligand and structure based virtual 
screening, are two methods in the wide library of methodologies that have become available 
with the advent of Computer-Aided Drug Discovery and Development (CADDD) (80). 
Modern methods of CADDD are targeted searches for compounds that affect a target protein 
in a desired fashion, preferably with a great deal of specificity as to avoid unwanted side effects. 
One of the areas where this has been of particular interest is in the development of 
pharmaceuticals to treat behavioral and cognitive disorders, as well as neuropsychiatric and 
neurodegenerative disorders (16, 17).  
 
1.5 Molecular Modeling 
In order to understand the intricacies of biology it is critical to study the macromolecular 
structures that are responsible for the molecular interactions which are the basis of biological 
function. The first structure determinations occurred in the 1950s and since then, both for 
proteins and nucleic acids, there has been a continuous advance in the understanding of how 
macromolecular structures are built and function (81). Alongside these advances in structural 
biology there have been advances in computational technology which have been harnessed as 
the technology developed in order to aid in the understanding of the complexities of large 
macromolecules. The computational advances allowed for the methodology known as 
molecular modelling to be developed, a method which allows for analysis and visualization of 
the structure of biological macromolecules in a three dimensional system (82). A good example 
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showing how far the technology has come since then can be seen by comparing the capabilities 
of molecular dynamics (MD) simulations then and now. An MD simulation is basically the 
simulation of molecules and how they interact with each other on a nanosecond (ns) to 
millisecond timescale, there is a more in-depth explanation of the method further below. The 
first MD simulations were run in the late 70s (81, 83, 84), and contained only a few hundred 
atoms, with current day computational power the MD simulations are regularly run containing 
systems of 50,000-100,000 atoms with some simulations reaching up to around 500,000 atoms 
with the appropriate computer facilities. The length of the simulations has also increased 
greatly, going from being in the low picoseconds to reaching multiple milliseconds if necessary 
(81). 
The advances in computation has made molecular modeling a valuable tool in the study of 
large macromolecules. The basis of the methodology is the creation of the computational 
models of the three-dimensional molecular structures of the macromolecules. The aim of the 
molecular models varies from project to project but a common goal is being able to relate 
biological activity to the structure of the molecule (81, 82). As molecules in nature always seek 
the lowest possible energy state this is something which must be reflected in any molecular 
model. In practice this is done by computing the theoretical potential energy of a molecule as 
a function of the positions of the constituent atoms. Molecular modeling has two main methods 
for computing this potential energy, the first of which is the Quantum Mechanics (QM) method 
and the second of which is the Molecular Mechanics (MM) method (83). Both methods have 
their own advantages and disadvantages, with the QM method being a more accurate and 
computationally intensive methods suited for systems of up to around 100 atoms and the MM 
method sacrificing some accuracy for speed, allowing it to handle significantly larger systems 
(85). 
 
1.5.1 Molecular Mechanics 
As mentioned previously molecular modeling has two methods for computing potential energy 
when doing molecular modeling, these being QM and MM. As QM takes into account the sub-
atomic particles when performing energy calculations, it is much computationally intensive 
than MM, which treats each atom as a single unit with its own force field which approximates 
the effects of sub-atomic particles through classical mechanics. There also exists hybrid 
methods, called QM/MM, which use QM methods in areas of interest and MM for the rest of 
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model system. This method has the advantage of providing greater accuracy in the area of 
interest as well as retaining some of the speed provided by MM (85). While this method is 
efficient it is also in some ways more difficult, the borders for QM calculations must be set and 
changes to these borders affect both the results and the time required to compute the results 
(86). Both QM and QM/MM have their own merits when used appropriately, the same can be 
said for MM. If a study does not require the level of accuracy QM provides then using only 
MM is less computationally intensive and therefore beneficial.  
With MM treating each individual atom as a single unit the force fields governing them become 
very important to the accuracy of the computer model. Each individual unit is governed by 
numerous energy terms, these terms describe the deformation of bond lengths, torsion angels 
and the bond angels between the various individual units. The computer model also requires 
energy terms that apply to non-bonded atom pairs, describing the attractive and repulsive forces 
of van der Waals forces and a term that considers the coulombic interactions between charges 
(82). Even with the numerous energy terms having to be taken into consideration for each atom 
MM is still, computationally, significantly faster with the atom being treated as a single unit 
rather than a collection of sub-atomic units (85). 
 
1.5.2 Force Fields 
In computational models using MM their collection of energy terms, mentioned above, are 
what make up the forcefield that is used to calculate the interactions between the atoms making 
up a molecule and between separate molecules. These energy terms have reference values for 
what an “unstrained” bond length, angle, torsion or nonbonded interaction is and this is used 
to calculate the total energy of a molecule by looking at deviations from these reference values. 
The term force field, when referring to MM, is a collection of empirically derived values of 
“unstrained” force constants (87). The basic formula used to describe force fields is possible to 
write in the following manner: 
Etot = Ebonded + Enonbonded 
Etot is the potential energy, while Ebonded and Enonbonded describes the covalent and noncovalent 
boning energy terms. This formula can be further subdivided, giving a clearer understanding 




Etot = (Ebond + Eangle + Edihedral) + (Eelec + Evdw) 
where Ebond describes bond stretching, Eangle describes angle bending and Edihedral describes the 
torsional energy terms. For the nonbonded energy terms there is Eelec which describes the 
electrostatic forces and Evdw which describes the van der Waals forces (87). 
All the energy terms that are used to build the force fields used in MM are empirically derived, 
meaning there are not any energy functions or parameters that are “correct”, but rather close 
approximations of the measurable phenomena of the natural world. What this translates to in 
computational models is slight variations in projects using MM with different force field 
models (88). 
 
1.5.3 Structure Determination 
In order to employ the use of computational methods in the study of a protein it is necessary to 
have the structure of that protein rendered in a virtual environment. There are several ways for 
a structure to be rendered virtually, with some methods being more accurate in the structure 
determination than others (89). Of methods that seek to determine the structures of proteins 
there are several, with the most common and powerful methods being X-ray crystallography, 
followed by Nuclear Magnetic Resonance (NMR) spectroscopy. An X-ray crystallography 
structure determination has no limitations on the size of the protein that is being determined, it 
is also the technique which provides the most precise atomic detail. The downsides to X-ray 
crystallography is that it requires a protein that can be crystalized, information regarding a 
proteins dynamics may also be limited if it is determined by X-ray crystallography. NMR 
spectroscopy does not require a protein to be crystalized, but rather works on macromolecules 
in solution. This makes NMR spectroscopy a technique suitable for use in cases where X-ray 
crystallography is not possible, however NMR spectroscopy does have a limitation on the size 
of the molecule it can determine (molecular weights below 50 kDa) and also has a lower 
resolution than that provided by X-ray crystallography (90). The two techniques can be used 
in conjunction and deliver complementary information, especially useful in the structure 
determination of small proteins (91). Of the entries in the PDB database 125271 of them were 
determined by X-ray crystallography, while 12206 were determined by NMR spectroscopy as 
of May 2018 (92). NMR spectroscopy is however the dominating technique for structure 
determination of molecules with a size of less than 10 kDa molecular weight (90).  
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There is also a third technique for structure determination, cryo-electro microscopy, which has 
recently achieved resolutions which allow for structure determination. This method involves 
the three-dimensional reconstruction of electron microscopy images, the methodology is based 
on the methods of X-ray crystallography and in earlier stages it required ordered samples, such 
as 2D crystals or helical arrays (93). The improvement in resolution in recent years have taken 
image resolutions from sub-10 Å resolution being significant 10 years ago to current times 
where sub-5 Å resolution is considered a common accomplishment. This method works best 
with biological molecules, especially those that are larger than 500 kDa, and may therefore be 
difficult to resolve with X-ray crystallography or NMR spectroscopy. Although the resolutions 
achieved using this method have improved they are still subpar when used alone compared to 
that achieved by X-ray crystallography. The use of both methods in conjunction can however 
be highly effective and achieve a potentially better result than using only one of the methods 
on its own (94). In the PDB database there are 2110 entries as of May 2018 that have been 
attributed to determination by electro microscopy, this is the smallest category be a large 
margin (92), but with further improved resolution there is promising potential that a larger 
portion of structures may in the future be determined through electro microscopy (94).  
If a project aims to study a protein which has yet to have its structure determined there is also 
a computational method that can be used to build a model of the target protein. This method is 
called homology modeling, and involves the construction of a computational model based on 
an already resolved protein that is homologous to the target protein and the amino acid 
sequence of the target protein. This creates a model of the target protein that should to a degree 
have the same or similar structure to the target protein, how accurate the model is depends on 
the sequence similarity with the homologous protein that was used as a scaffold for the model 
(95). The determination of structure through experimental methods is still a complex process, 
especially for membrane bound proteins. This makes homology modeling a key in silico tool 
for obtaining structural information on unresolved proteins. 
When a computational model has been acquired, whether it has been resolved from the target 
protein or if there has been created a homology model, the structure needs to assume a low-
energy conformation. The need for a low-energy conformation in computational models comes 
from molecules spontaneously taking on low-energy conformations in nature, as would be their 
natural state. It is in this state the proteins are assumed to interact with and bind to their ligands 
in nature, making it crucial to minimize the energy of a resolved structure to create as similar 
an environment as possible between in silico and nature. For those working in silico there is a 
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computer-based method called Energy Minimization which seeks optimize the computational 
model towards the low-energy state the molecule is thought to assume in a natural environment 
(28). 
 
1.5.5 Molecular Dynamics 
One of the most important tools for the computational study of the physical basis and function 
of biomolecules is MD simulations (96). Biological functions are based on the interactions of 
molecules and many molecular interactions only occur as a consequence of macromolecular 
structures. This makes the study of these macromolecular biomolecule structures paramount to 
truly be able to decipher biological functions. Advancements in technology and improved 
computing power has allowed MD simulations to reach simulation times that are close to 
relevant within biological timeframes. This has allowed the technique to be used more 
effectively to understand the relationship between structure and function that biomolecules 
such as transporter proteins and membrane receptors possess. It also allows for the study of 
how these large macromolecular structures interact with smaller molecules that affect their 
function (81). 
An MD simulation is an in silico simulation of a molecular system that is designed to reproduce 
how molecules interact as closely as possible. The molecules of the system are defined by the 
force fields of the MM model that the system is using. The movement of molecules within the 
simulation is calculated at regular intervals called frames (81). Newton’s second law of motion 
is used to calculate new velocities and positions for atoms in each new frame, once the 
calculations are complete the atoms are move to their new position generating a new 
conformation which is subsequently added to the MD simulations trajectory (28). For the MD 
simulation Newton’s second law of motion is solved as: 
Fi (t) = mi ai (t) 
Here Fi is the force that is applied to atom i at time t, mi describes the mass of the atom i and 
ai describes the acceleration of atom i at time t. With each new frame being a new t, the 
simulation continues for the preset number of frames with a set in-system time-interval between 




1.5.6 Docking and Scoring 
For the prediction of the binding orientations and affinities of ligands in the binding sites of 
their macromolecular targets docking is a widely used method. Most modern docking programs 
make use of a semi-flexible docking approach as it is not computationally feasible to have both 
the ligand and receptor molecules fully flexible. In the semi-flexible approach, the smaller 
ligands are flexible while the macromolecule it is to be docked into is rigid (97). There is also 
an approach that introduces protein flexibility into the docking by performing refinement of 
protein side chains, and in some occasions also the protein backbone, that is in the vicinity of 
the docked ligands, a method called induced-fit docking (98). The increased flexibility 
introduced into the binding site by induced-fit docking (IFD) protocols allows for the ligands 
to be placed in conformations not allowed by a rigid protein and allows for finding a position 
in the binding site where the ligand is placed more optimally (98). 
When a ligand has been docked into a protein there is a need to score the docking, a number 
that describes the interaction between the ligand and the protein. A scoring function can this 
way be used to rank a large number of orientations for a ligand in a binding site to find the 
ligands optimal placement, it can also be used for the prediction of an absolute binding affinity 
between a ligand and a protein (99). The Gibbs-Helmholtz equation is used for the calculation 
of the binding free energy (ΔG) of a docking pose. In the Gibbs-Helmholtz equation: 
ΔG = ΔH – TΔS = -RT ln Ki 
ΔH is the enthalpy, T is the temperature in Kelvin, ΔS is the entropy, R is the gas constant and 











2. Aim of the Study 
One aim of the current study is to gain a greater understanding and proficiency in the use of 
both computational (in silico) methods for studying biologic molecules as well as some 
laboratory (in vitro) methods for testing biologic molecules. The study is essentially separated 
into two separate but related parts. The first part is the computational study of SERT, which 
will itself be split into two separate parts. The second part is the laboratory work which will be 
focusing on identification of putative new GABAB receptor compounds as a part of a larger 
study in the Molecular Pharmacology and Toxicology research group. Compounds predicted 
as putative GABAB receptor compounds in a previous virtual screening approach (Evenseth et 
al. 2018, unpublished work) will be tested by in vitro functional studies. 
The computational part of the study will be performed first, and as stated previously will be 
divided into two parts. Each of these parts will employ different methods in order to broaden 
the scope of methods used and allow for a wider understanding of computational methods to 
gain greater proficiency in.  
The first of the parts is MD simulations, which will be performed using the recently (53) 
crystalized structures of the SERT protein. There will in total be performed four MD 
simulations, each at a length of 200 ns. The ligands to be used during the simulations are (S)-
citalopram, a known inhibitor of SERT, and serotonin, which is the endogenous substrate of 
SERT. As (S)-citalopram is the native ligand of both crystal structures that were used for the 
project, as well as being a well-tolerated SSRI (13), it was chosen to be used as an inhibitor for 
the computational part of the project. The MD simulations will focus on the central site of the 
5I71 crystal structure (53) and the allosteric site of the 5I73 crystal structure (53). For both the 
central and allosteric site (S)-Citalopram and serotonin will have their own simulations without 
the presence of another ligand in the model system. 
The second part of the computational study is the docking of SERT inhibitors. These inhibitors 
fall into two groups themselves. The known inhibitor of SERT, which is (S)-citalopram, and 
inhibitors found in an earlier virtual ligand screening approach of SERT using a homology 
model. The inhibitors from the previous homology model study have been experimentally 
verified as functional inhibitors of SERT using [3H]-citalopram as a radioligand (100). The X-
ray structure of SERT indicates that (S)-citalopram is capable of binding to both the central 
site and the allosteric site of SERT. It is therefore not clear if the identified inhibitors bind to 
the central, allosteric or both sites on SERT. 
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The specific goals of the computational parts of the study are as following: 
- Gain a greater understanding of and higher proficiency in the use of computational 
methods used in the study and analysis of biological molecules. 
- Elucidate the molecular mechanism of action of (S)-citalopram and serotonin by 
studying the interactions with surrounding amino acids, ions and water molecules in 
both the central and allosteric site over the course of a 200 ns MD simulation. 
- Compare the results of the induced fit docking of inhibitors from the previous 
experimental verification with the results of the MD simulation with a focus on ligand-
protein interactions in both binding sites. 
- Attempt to elucidate a correlation between docking score in the crystal structure with 
the previous results of the experimental verification of the inhibitors (100). 
The laboratory part of the study will be performed after the computational part. This part will 
focus on the acquisition and practice of laboratory techniques during in vitro binding studies 
using a functional cAMP assay in order to verify predicted hits from a virtual screening 
approach. 
The goals of the laboratory parts of the study are as following: 
- Gain a greater understanding of and higher proficiency in the use of laboratory 
techniques. 
- Experimental verification of predicted hits from a previous in silico virtual screening 












3.1 Computational Work 
3.1.1 Software and Databases 
3.1.1.1 Software 
Schrödinger Software Release 2017-2 
The 2017-2 version of the Schrodinger software package is a collection of tools designed for 
molecular modeling, drug design and the study of molecular structures. 
The small molecule discovery suite put together by Schrodinger is a powerful tool in the study 
of complex biological proteins and their interactions. The suite possesses a wide array of tools 
that allow many different approaches in the study of the target of interest. Among the suites 
capabilities are the visualization of the molecules ranging from single atoms all the way to 
complex proteins, the ability to analyze the structure of a target and its binding modes, 
numerous utilities for ligand structures, the ability to simulate the targets motion in an in silico 
environment and tools for analyzing the results of the targets simulated motion. The tools that 
were used during this study include the unified interface Maestro (101), the Protein Preparation 
Wizard (102, 103), the protein structure prediction tool Prime (104), the ligand preparation 
module LigPrep (105), the Residue Scanning module (106), the Desmond molecular dynamics 
system module (107), the Simulation Interactions Diagram (107), the Event Analysis module 
(107) and the Induced Fit Docking protocol (108, 109).  
 
3.1.1.2 Databases 
The Protein Data Bank 
The Protein Data Bank (PDB) (92) archive (https://www.rcsb.org/) is the universal repository 
of data on the 3D structure of large biological molecules, this includes proteins and nucleic 
acids. There are several methodologies used in acquiring the structures that are submitted to 
the PDB archive, these are X-ray crystallography, NMR spectroscopy and cryoelectron 
microscopy. Most scientific journals requiring that any solved structures be submitted to the 




The Orientations of Proteins in Membranes Database 
The Orientations of Proteins in Membranes (OPM) (110) Database 
(http://opm.phar.umich.edu/) provides spatial orientations for membrane proteins from the 
PDB database with respect to the hydrocarbon core of the lipid bilayer. The spatial orientation 
provided for the available proteins has the protein positioned in the lipid bilayer, by having the 
transfer energy from water to the membrane minimized it is possible to adjust the thickness of 
the lipid bilayer. The OPM database contains every unique experimental structure of 
transmembrane proteins (110). 
 
The Universal Protein Resource 
The Universal Protein Resource (UniProt) (111) (www.uniprot.org) contains a comprehensive 
collection of the worlds protein sequences and annotation data. Many of these entries are 
obtained from genome sequencing projects. The database contains extensive data on the 
structure and function of registered proteins. The information the database contains is acquired 
from research literature, with most journals requiring that any relevant data be submitted to the 
database. The UniProt database is a collaborative work between the Protein Information 
Resource, European Bioinformatics Institute, and the Swiss Institute of Bioinformatics (111). 
 
ChEMBL 
The ChEMBL database (https://www.ebi.ac.uk/chembl) is a large-scale open database of 
bioactivity. The majority of the databases bioactivity data content originates from medicinal 
chemistry literature. This data has a myriad of applications, among them allowing researchers 
to identify compounds known to interact with potential therapeutic targets, investigating 
compounds with similar features and the identification of potential off-target effects for 







3.1.2 Computational Methodology 
For the computational part of the study the work was carried out, generally, in accordance with 
the flowchart below (Figure 6). Exceptions to the methodology presented in the flowchart are 
mostly in regards to some steps having to be repeated for verification, this mostly relates to the 
docking steps. 
 
Figure 6: The figure displays a flowchart of the computational methodology that was employed 
in the completion of this project. 
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3.1.2.1 Crystal Structure Selection 
For the computational components of the study it was necessary to have the structure of SERT 
as an in silico model. Previous studies (54, 113, 114) have used homology models of SERT for 
this, but recently a number of models were rendered through X-ray crystallography (53). This 
allowed for the current study to select a rendered crystal structure to be used for MD 
simulations and docking studies. The structures that were selected were used for both the MD 
simulations as well as for the docking study, the primary criteria for their selection was 
therefore their resolution and that they had the inhibitor (S)-citalopram bound as their ligand. 
Of the two structures that were selected one had (S)-citalopram bound to only its central site 
and a resolution of 3.15 Å (PDB ID 5I71) while the second selected structure had (S)-
citalopram bound to both the central and allosteric sites and had a resolution of 3.24 Å (PDB 
ID 5I73). The use of the same ligand, (S)-citalopram, ensured a greater degree of consistency 
between the structural conformation of the structures, a feature intended to give less deviation 
in the results of the docking study. 
 
3.1.2.2 Crystal Structure Preparation 
The preparation of the rendered crystal structures for the use in computational studies started 
with the use of the Residue Scanner module (106) to reverse mutations made to the amino acid 
sequence of SERT to enable the rendering of the structure through X-ray crystallography. The 
mutations introduced to amino acid 110, 291 and 439 to increase thermostability were reversed. 
In addition the surface exposed cysteines, amino acids 554 and 580, were mutated to alanine 
in the crystal structure. These mutations were also reversed back to cysteine during the crystal 
structure preparation. With the mutations reversed the structures were processed with the 
Protein Preparation Wizard (102). The first step is the preprocessing of the structure, which 
was carried out with the default settings apart the generation of het states using Epik (115) had 
the pH set to 7.0 +/- 0.2. In addition to the default settings, Prime (116) was also used to fill in 
any missing side chains or missing loops and the termini were also capped. Once preprocessing 
was completed the preparation of the protein structure moved on to the review and modify 
stage. Here the workspace was analyzed and any additions to the crystal structure for the sake 
of the crystallization process were removed. All water molecules in the system were also 
removed. With the review and modification stage completed the final stage of the protein 
preparation was the refine stage. The first step here was the H-bond assignment, which was 
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carried out using the default settings. The second step was the restrained minimization, which 
was also carried out with the default settings and the default OPLS3 force field. 
 
3.1.2.3 Ligand Selection 
For the computational part of the study ligands had to be selected for both the MD simulations 
as well as for the docking study. For the MD simulations, as the focus here was studying the 
interactions of the substrate and an inhibitor with the amino acids of the central and allosteric 
binding sites, serotonin and (S)-citalopram were selected. Serotonin is the substrate of SERT 
(44) and therefore seeing how it interacts with the amino acids of SERT while it is in its 
outward-open conformation is of interest. (S)-citalopram is an SSRI, an inhibitor of SERT 
(117) and seeing what amino acids it interacts with to achieve inhibition and comparing this 
with what serotonin interacts with is the focus of the MD portion of the computational study. 
(S)-citalopram was also the ligand of the selected crystal structures and the structures are 
therefore not expected to undergo any significant structural changes over the course of the MD 
simulations. It is however interesting to identify the structural consequences upon the SERT 
structure when it binds a substrate or an inhibitor. 
For the docking study ligands were selected from a previous study (100), which had created a 
ranked list of compounds that had been initially run through virtual screening using a homology 
model of SERT before being experimentally tested. The ligands were arranged into clusters 
based on structure and the compounds with the best experimental values in a competitive assay 
against [3H]-citalopram were selected from each of the clusters for use in the docking study. 
When selecting ligands the experimental values that were considered were the percent of 
inhibition a compound achieved, with higher being better, and also a low Ki. For most clusters 
the highest ranked compound was selected, any clusters that did not have compounds with a Ki 
of less than 1000 nM were not included in the docking study. A total of 15 ligands were selected 
from 13 clusters for the docking study, the docking study also included (S)-citalopram as a 






3.1.2.4 Ligand Preparation 
The ligands that were selected for both the MD simulations and the docking study were run 
through Schrodingers LigPrep module (105). During the ligand preparation using the LigPrep 
module the default settings were used apart from setting the target pH of possible states to be 
generated to 7.0 +/- 0.2. 
 
3.1.2.5 Induced Fit Docking 
In this project Schrödinger Induced Fit Docking protocol (109) was used to dock the selected 
ligand, serotonin, into the prepared crystal structures of SERT for both the central and allosteric 
binding sites. Induced Fit Docking was also used in the study of the experimentally verified 
compounds that had been selected for the Docking part of the project.  
For the Induced Fit Docking that was carried out on the prepared ligands the default OPLS3 
force field was used with the protocol set to extended sampling, which would generate up to 
80 poses for each ligand. The ligand binding pocket in the receptor was defined by selecting 
the ligand, (S)-citalopram, that was in its default position in the 5I71 structure for the central 
site, and 5I73 structure for the allosteric site. All other settings were set to default for Induced 
Fit Docking jobs.  
 
3.1.2.6 Molecular Dynamics Simulation 
Four 200 ns MD simulations of SERT were carried out using Desmond (107). The MD 
simulations were performed with the PDB ID 5I71 crystal structure for the central site 
simulations and the PDB ID 5I73 crystal structure for the allosteric site simulations. Of the four 
simulations two were of the central site and two were of the allosteric site, each site had one 
simulation with serotonin and another with (S)-citalopram. 
For the (S)-citalopram simulations the placement of the ligand was left as it was in the crystal 
structure. The ligand was removed for ligand preparation and was later merged back into the 
crystal structure in the same position as before the ligand preparation, this was done for both 
the (S)-citalopram simulations in the central site and the allosteric site. For the simulations 
using serotonin the ligand was first prepared, before being placed into each respective binding 
pocket. For the central binding pocket it was placed by Induced Fit docking, but for the 
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allosteric site this method failed and it was instead merged into the allosteric site in the same 
position as the best scoring serotonin docking pose that was generated for the allosteric binding 
pocket using Induced Fit docking. The reason the SP docking failed is not clear, but the same 
result was achieved by merging the entries. All structures were minimized once more after 
having their ligands reinserted. 
With the protein-ligand complex ready the next step was the creation of the model system, this 
was done in Schrodinger’s System Builder module. The OPLS3 force field was used for the 
amino acid interactions and the water model simulation used the TIP3P method. As SERT is a 
membrane protein an important part of the model system setup is the addition of the membrane. 
For the addition of the membrane the structure was prealigined on a template that was acquired 
from the OPM database, the membrane itself was setup with the POPE (310 K) membrane 
model. With the membrane setup settings completed the boundary conditions of the model 
system were set. Here a 10 Å × 10 Å × 10 Å water box with orthorhombic dimensions was 
used, as is the default setting in the system builder. The final stage of the model system 
construction was the balancing of the net charge with Cl- ions to neutralize the system, followed 
with the addition of a salt concentration of 0.15 M. For the added salt concentration Na+ was 
used as the positive ion and Cl- was used as the negative ion. 
Before initiating the MD simulations each of the model systems were run through Schrodingers 
relaxation protocol for membrane-bound proteins using the command line. The script for this 
was run before the MD simulation, which is why the default option to relax the model system 
before beginning the simulation was deselected.  
For the MD simulation the system was subjected to 310 K for 200 ns, 200 000 ps, using the 
default NPT ensemble class. The recording interval was set to 50 ps. The pressure was left at 
the default 1.0132 bar and the option to relax the model system before the simulation was 








3.1.2.7 Analysis of MD trajectories 
The MD simulations were analyzed with the Simulation Interactions Diagram (SID) module 
(107) and also the Event Analysis module (107). The data provided by the SID module was 
included in the results, among this was the Protein-Ligand RMSD, the Protein RMSF and 
Protein-Ligand contact analysis. The Event Analysis module was used to look for differences 
in the behavior of amino acids in the central site by measuring the varying distances over the 
course of the simulations between opposing amino acids known to be important (TYR95, 
ASP98, ILE172, ASN177, PHE341, SER438) for the function of SERT (118). The 
measurements data was then plotted using the data presentation options of the Event Analysis 
module. 
 
3.1.2.8 Analysis of docking results for experimentally verified SERT antagonists 
The docking portion of the study gave docking scores for every compound for each binding 
site. This data could then be compared between binding sites, with the experimental Ki values 
of the compounds, and with the degree of inhibition that the compounds exhibited. These data 
points were charted to see if there was any correlation between them. The amino acids each 














3.2 Experimental testing of potential GABAB receptor antagonists 
3.2.1 Materials 
Materials purchased from DiscoveRx: 
• cAMP Hunter™ CHO-K1 GABBR1+GABBR2 Gi Cell Line (Cat.# 95-0165C2) 
o The CHO-K1 Wild Type (WT) cell line was provided by the Tumor biology 
research group of UiT, The Arctic University of Norway. 
• AssayComplete™ Revive CHO-K1 Medium (Cat.# 92-0016RM2S) 
• AssayComplete™ CHO-K1 Cell Culture Kit 35 (Cat.# 92-0018G2R2) 
• AssayComplete™ Cell Detachment Reagent (Cat.# 92-0009) 
• AssayComplete™ Freezing Reagent F2 (cat.# 92-5102FR) 
• HitHunter® cAMP Assay for Small Molecules (cat.# 90-0075SM2) 
• White clear bottom, tissue culture treated 384-well (cat.# 92-0013) 
Chemicals purchased from Sigma-Aldrich: 
• CaCl2 (Cat.# C7902)  
• HEPES (Cat.# H3375) 
• MgCl2·6H2O (Cat.# M9272) 
• KCl (Cat.# 746436) 
• NaCl (Cat.# 746398) 
• D-(+)-Glucose (Cat.# G7021) 
• NaOH (Cat.# 30620) 
• GABA (Cat.# A5835) 
• DMSO (Cat.#  472301) 
• Water soluble forskolin NKH477 (Cat.# N3290). 









3.2.2.1 Cell culture and harvesting 
A cell culture was started with a CHO-K1 cell line stably co-expressing the human GABAB(1b) 
and GABAB2 receptor subunits (DiscoveRx, Cat.# 95-0165C2) using the cell culture reagents 
and guideline from DiscoverX.  
A vial of cells (GABAB or CHO-K1 WT) that had been cryopreserved in the gas phase of a 
liquid nitrogen tank was quickly thawed using a 37°C water bath. The cells were thawed under 
sterile conditions until only a small ice crystal remained, the majority of the cell pellet was 
thawed at this point. The thawed cells were then immediately transferred from the 
cryopreservation vial over into a sterile 15 ml tube containing 7 ml of pre-warmed culture 
medium. For the WT cells there was no antibiotics added to the culture medium. The next step 
was the centrifugation of the cells at 300 G for 4 minutes. The supernatant was then aspirated 
and the cell pellet immediately resuspended in 10 ml of pre-warmed culture medium for the 
GABAB cells and 15 ml pre-warmed culture medium for the WT cells (no antibiotics for WT). 
The following step was the transfer of 5 ml of (GABAB) cell suspension into two T25 flasks, 
one intended as a backup. The T25 flasks were then marked and grown at 37°C, 5% CO2. For 
the WT cells the 15 ml of cell suspension was transferred to a T75 flask, marked and grown at 
37°C, 5% CO2. The cells reached >70% confluency after about 24 hours for the WT cells (T75) 
and between 36-48 hours for the GABAB cells (2x T25). The WT cells could be harvested for 
assay after 24 hours, the GABAB cells had to first be grown in two T25 flasks, then transferred 
to two T75 flasks (one for each T25) and grown again. 
With the (GABAB) cells at >70% confluency the medium in the culture flasks was aspirated 
and the cells were quickly washed with 37°C Ca+2/Mg+2 free Phosphate-buffered saline (PBS) 
3 times. Once the final wash of 37°C PBS was aspirated, 0.8 ml of AssayComplete™ Cell 
Detachment Reagent was added to the T25 flask and it was then incubated at 37°C for 2 min, 
at which point the cells are detached. The cells were then collected using 20 ml of 37°C PBS 
into a 50 ml conical tube, which was subsequently centrifuged for 4 minutes at 300 G. Once 
the centrifugation was complete the supernatant was aspirated and the cell pellet was re-
suspended using 15 ml of culture medium. The cell suspension was then transferred over to a 
T75 flask for continued growth. The second T25 flask underwent the same procedure. 
The (GABAB) cells were harvested after 2 days of growth for the cAMP functional assay, when 
the cells reached a confluency of about 75%. The WT cells were harvested from their T75 flask 
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after 1 day of growth for cAMP assay, at which point they had reached about 70% confluency. 
On the day of the assay culture medium was first aspirated from the T75 flask and the cells 
were quickly washed with 37°C PBS 3 times in quick succession. Then, 1.6 ml of 
AssayComplete™ Cell Detachment Reagent was quickly added to the T75 flask and incubated 
at 37°C for 2 min. The cells were then collected using 40 ml of 37°C PBS into a 50 ml conical 
tube, before being centrifuged for 4 minutes at 300 G. Once the centrifugation was complete 
the supernatant was aspirated and the cell pellet was re-suspended using 20 ml assay buffer 
HBSS (HEPES-buffered hank’s balanced salt solution: 2 mM CaCl2, 5 mM D-Glucose, 10 mM 
HEPES, 3 mM KCl, 1 mM MgCl2, 136 mM NaCl, pH adjusted to 7.4 at 18°C using 1 M 
NaOH). The cell suspension was centrifuged again for 4 minutes at 300 G, with the supernatant 
subsequently being aspirated and the cell pellet re-suspended using 3 ml of the assay buffer.  
For determining the cell concentration, 40 µl of fresh cell suspension was mixed with 40 µl of 
0.4% trypan triple blue solution. 10 µl of this mixture was then loaded into two Countess® 
chamber slides and counted using a Countess® automated cell counter. The cells were then 
quickly diluted to a concentration of 0.5 million cells/ml and incubated at the assay volume of 
30 µl/0.2 ml tube in an assay plate at 18°C for 1 hour before the test compounds were added 
(Figure 7). 
 





3.2.2.2 Test compound preparation and testing on cells 
The test compounds dissolved in 100% DMSO with a stock concentration of 10 mM transferred 
to aliquots and stored at -20°C freezer. The solubility of the test compounds was tested in assay 
buffer at a concentration of 60 µM. Five of the test compounds were found to have good and 
stable solubility, the other five test compounds were not soluble at 60 µM or 30 µM 
concentration, but were soluble in 5 mM D-glucose solution at a concentration of 30 µM. The 
final concentration of the test compounds when used in the assay is therefore 10 µM and 5 µM. 
On the day of the assay, the frozen test compounds were retrieved from the freezer and placed 
at room temperature to thaw. A mixture of forskolin, GABA (for the GABAB expressing cells) 
and test compounds was prepared in assay buffer at the desired concentrations. When the cells 
had finished their 1 hour of pre-incubation at 18°C the compound mixture was added, 15 µl of 
it, to each of the 0.2 ml tubes (Figure 7). For each of the components of the mixture the final 
assay concentration was: 1µM GABA (for GABAB expressing cells), 30 µM Forskolin and 10 
µM or 5 µM test compound (depending on solubility of compound). For the controls only 1 
µM GABA (for GABAB expressing cells) and 30 µM Forskolin mixture was used. The reaction 
was allowed 25 minutes before the cAMP reagents were added.  
 
3.2.2.3 Measurement of cAMP levels 
Once the reaction had been active for 25 minutes at 18°C the cAMP levels were measured 
through the use of the HitHunter® cAMP Assay for Small Molecules (DiscoveRx) by 
following the instructions provided by the manufacturer. The cAMP antibody reagent and the 
cAMP working detection solution were both added to all the wells in rapid succession, which 
was followed by an incubation period of 1 hour in the dark at 18°C. After the 1 hour incubation 
period the cAMP solution A was finally added to all the wells and the wells were left for a 12-
14 hour incubation at room temperature in the dark. 
After the 12-14 hour incubation the assay mixture was transferred in the dark to a white clear 
bottom tissue culture treated 384-well plate. For each well 50 µl was transferred, each 
compound was given triplicate wells. The cAMP signal was then immediately read on 
ClarioStar® plate reader (BMG LABTECH) for the luminescence readout. The results of the 





4.1 Molecular Dynamics 
The four MD simulations (Figure 8) that were run for this study provided a very significant 
amount of data. The choice was made for the data to be analyzed from two points, these were 
the structural dynamics of the protein over the course of the simulation and the interactions 
between the protein and the ligand over the course of the simulation. As the MD simulations 
were rather short, only 200 ns, no substantial changes were expected in the proteins overall 
structure, with the focus instead being on stability of the protein model and the movement of 
amino acids throughout the simulation. For the protein-ligand interactions the focus was on the 
interactions between the ligand and the various amino acids in the binding pockets. Whether 
these interactions were consistent with what had been found to be key amino acids in the central 
site or not, and also investigating which amino acids in the allosteric site were favored by the 
ligands. 
 
Figure 8: The above figure shows the ribbon diagrams of the SERT crystal structures used for 
the MD simulations. (A) is the PDB ID 5I71 crystal structure with (S)-citalopram in the central 
site, was used for all MD simulations with a ligand in the central site. (B) is the PDB ID 5I73 
crystal structure with (S)-citalopram in the allosteric site, was used for all MD simulations with 
a ligand in the allosteric site. 
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4.1.1 Protein Structure Analysis 
4.1.1.1 Protein-Ligand RMSD 
In order to measure how significant a change there has been in the placement of a selection of 
atoms over the course of an MD simulation compared with a reference frame the Root Mean 
Square Deviation (RMSD) is used. The RMSD is calculated by measuring the average change 
in displacement for the atom selection in a particular frame with respect to a reference frame. 
To find the RMSD of a MD simulation timeframe this must be done for every frame in the 
trajectory. The Schrodinger Simulation Interaction Diagram module by default generates a 
Protein RMSD and a Ligand RMSD when analyzing and MD simulation. The Protein RMSD 
allows for a deeper understanding of a proteins structural conformation throughout the MD 
simulation and can also give indications if the simulation is equilibrated or not. The Ligand 
RMSD shows an indication of the degree of stability the ligand possesses with respect to the 
protein and its binding pocket. If the Ligand RMSD has significantly higher values than that 
of the Protein RMSD then this is an indication that the ligand has moved away from its initial 
binding site (107).  
 
Figure 9: The above figure displays the plots showing the RMSD evolution of both SERT (left 
Y-axis, Cα) and the designated ligand for each respective simulation (right Y-axis, Lig fit Prot) 
compared with their reference position at the initiation of each of the respective simulations, 
the distance values are in angstrom (Å). The X-axis for each of the plots shows the timeframe 
of the simulation in ns. The figure is organized by binding pocket, the two top most plots are 
for the central site and are for (A) (S)-citalopram and (B) serotonin. The two bottommost plots 
are for the allosteric site and are for (C) (S)-citalopram and (D) serotonin.  
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For the Protein RMSD all the protein frames are aligned on the reference frame backbone, with 
the RMSD then being calculated based on the atom selection. The Ligand RMSD, Lig fit Prot, 
displays the RMSD of the ligand at the point where the protein-ligand complex is initially 
aligned on the protein backbone of the reference complex and then the RMSD of the ligand 
heavy atoms is measured (107).  
As can be seen from Figure 9 the Protein RMSD and Ligand RMSD was calculated for each 
of the four simulations that were performed for the project. The (A) section of the figure gives 
an overview for (S)-citalopram in the central site, (S)-citalopram is the native ligand of the 
crystal structure and both the protein and the ligand remained quite stable for the duration of 
the simulation. For the (B) section of the simulation, which had serotonin in the central site we 
see that the protein is quite stable throughout the simulation. The ligand also remains mostly 
stable with a few spikes in movement. Comparing (S)-citalopram and serotonin in the central 
site shows that while both were stable for the duration of the simulation it is clear that serotonin 
moved substantially more from its reference frame in the beginning of the simulation than (S)-
citalopram did. For the allosteric simulation with (S)-citalopram (C), which is again the native 
ligand of the crystal structure, the protein remained stable throughout the simulation. The 
ligand however underwent numerous small spikes throughout the first 60 ns before increasing 
significantly and subsequently becoming stable for the remainder of the simulation. The 
allosteric simulation with serotonin (D) saw the protein being stable for the duration of the 
simulation, while the ligand underwent numerous spikes throughout the simulation before 
reaching apparent stability at 150 ns. The (D) simulation was the one that saw the most activity 
with the ligand, where it moved around significantly throughout the simulation. The ligand did 
not however leave the allosteric binding pocket during the simulation, despite the relatively 









4.1.1.2 Protein RMSF 
The movement of amino acids along the protein chain can be characterized by the Root Mean 
Square Fluctuation (RMSF).  
 
Figure 10: The above figure displays the plots showing the Protein RMSF evolution of all four 
MD simulations. The X-axis for each of the plots display the residue index, i.e. each point 
along the X-axis represents an amino acid belonging to SERT ordered after residue number. 
The Y-axis for each of the plots displays degree of fluctuation by each amino acid in angstrom, 
functionally characterizing local changes along the protein chain. The figure is organized by 
binding pocket, the two top most plots are for the simulations with the ligand in the central site 
and are for (A) (S)-citalopram and (B) serotonin. The two bottommost plots are for the 
simulations with the ligand in the allosteric site and are for (C) (S)-citalopram and (D) 
serotonin. 
 
The plots in Figure 10 show the amount of fluctuation individual amino acids underwent over 
the course of the simulation. The peaks in the plot are indicative of areas that underwent the 
most fluctuations, the degree of the fluctuation can be seen on the Y-axis of Figure 10. The 
amino acids that make up the secondary structure elements of the protein, such as α helices and 
β strands, normally have a higher degree of rigidity than parts of the protein that are not part of 
a secondary structure. The secondary structure parts of the protein are therefore expected to 
fluctuate less than the proteins loop regions (107).  
When examining the plots in Figure 10 with the amino acids known to be in the central and 
allosteric binding sites (Figure 11, Table 2, Table 3) in mind it also becomes apparent that for 
the most part these amino acids have fluctuations that fall on the lower end of the spectrum. 
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The amino acids that interact with the ligand but still undergo significant fluctuations are the 
ones in the range above 480 residues, although there are dips down into lower fluctuation 
degrees in some of the simulations. For the late five hundred amino acids it seems the 
fluctuations are especially extreme in the MD simulation with serotonin in the central site 
(Figure 10, (B)). For the other simulations, and the simulations in general most amino acid 
fluctuations are fairly similar between simulations with only a few variations. There also seems 
to be some variations in fluctuation from the difference in crystal structure, although this may 
also potentially be caused by these models having no ligand in the central site. 
 
4.1.2 Protein-Ligand Interactions Analysis 
4.1.2.1 Protein-Ligand Contacts – Binding Type 
The interactions between the protein and the ligand can be monitored throughout the entirety 
of the MD simulation. These interactions can then be categorized as seen in the figure below 
(Figure 11). The stacked bar charts are normalized over the course of the trajectory. An 
example of this in practice would be that a value of 0.5 means that the specific interaction was 
maintained for 50% of the simulation time. It is possible for the values to be greater than 1.0 
by virtue of some protein residues making multiple contacts of the same subtype with the ligand 
(107).  
Here we look at what types of interactions the ligand of each simulation had with the amino 








Figure 11: The figure displays the amino acids that the ligands interacted with over the course 
of each of the four the simulations. The figure is organized by binding pocket, the two top most 
bar charts are for the central site and are for (A) (S)-citalopram and (B) serotonin. The two 
bottommost bar charts are for the allosteric site and are for (C) (S)-citalopram and (D) 
serotonin. Each of the ligands was placed in the respective binding site of SERT for that 
simulation from the onset of the simulation, each entire system having already been run though 
a relaxation protocol script for membrane bound proteins before initiating their MD simulation. 
The Y-axis of each bar chart displays a numerical value equal to the percentage of the time that 
residue interacted with the ligand over the course of the simulation, values above 1.0 (100%) 
are possible if the amino acid had multiple contacts with the ligand. The X-axis of each bar 
chart displays the names of the interacting amino acids. 
 
As can be seen from Figure 11 there were numerous connections between the amino acids of 
the binding pockets and the ligand. It is also quite apparent that the ligands, both (S)-citalopram 
and serotonin, interacted with significantly more amino acids when in the allosteric binding 
pocket than when in the central binding site. To be precise (S)-citalopram interacted with 18 
amino acids in the central binding site and 33 amino acids in the allosteric binding site. Which 
is slightly lower than for serotonin in the central site, with serotonin interacting with 23 amino 
acids in the central binding pocket. For the allosteric binding pocket serotonin interacted with 
fewer amino acids, interacting with 31 over the course of the simulation. 
The amino acids that each ligand had a high degree of interaction with over the course of the 
simulations were for the most part within 3Å of the ligand at the end of the simulation, at which 
point the systems for each MD simulations was quite stable with only small overall 
fluctuations. For the central site simulation with (S)-citalopram the amino acids that showed 
the highest degree of interaction were TYR95, ILE172 and TYR176 (Figure 11 (A)). TYR95 
had the highest interaction value, at about 1.7, which means the interaction was maintained for 
the majority of the simulation and also had multiple interactions simultaneously with the 
ligand. As can be seen from the above figure, the interactions with TYR95 were of both a 
hydrophobic nature and in the form of H-bonds. ILE172 and TYR176 had values of about 0.8 
and 0.9 respectively and were solely hydrophobic in nature. As can be seen from Figure 12 (A) 
all three of these amino acids were within 3Å of (S)-citalopram at the end of the simulation.  
The central site simulation with serotonin showed that the amino acids with the highest degree 
of interaction were TYR95, ASP98 and SER438 (Figure 11 (B)). These amino acids had 
interaction values of about 1 for ASP98 and SER438, with TYR95 having the highest 
interaction value at nearly 2.0. As can be seen the figure above, the interactions with the TYR95 
amino acid were of both a hydrophobic nature and also in the form of H-bonds. The interactions 
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of both ASP98 and SER438 were for the most part H-bonds with the ligand, but a small portion 
of ASP98’s interactions were ionic and a slightly larger portion of SER438’s interactions were 
in the form of water bridges. Serotonin also had ILE172, SER336 and PHE341 which 
maintained a moderate degree of interaction at the 0.5-0.3 level. These interactions were of a 
hydrophobic nature for ILE172 and PHE341, while SER336 had H-bond interactions with the 
ligand. As can be seen from Figure 12 (B) both the high and moderate degree interaction value 




Figure 12: The above figure displays the Schrodinger Maestro workspace containing each 
respective MD simulation ligand and any amino acids that where within 3Å of the ligand in the 
central site at the end of the 200 ns simulation. (A) is for (S)-citalopram and (B) is for serotonin. 
Color coding of atoms: red; oxygen, blue; nitrogen, green; ligand carbon atoms, gray; amino 




The allosteric simulations showed the ligands interacting with a larger quantity of amino acids, 
but there were no interaction values that exceeded 1.2, unlike the central site which had an 
interaction value for TYR95 exceeding 1.6 with both (S)-citalopram and serotonin. For the 
simulation with (S)-citalopram in the allosteric site the only amino acid that showed a high 
degree of interaction comparable to that seen in the central site was PHE335 (Figure 11 (C)) 
which had an interaction score of 1.0. The interaction between PHE335 and (S)-citalopram in 
the allosteric site was of a hydrophobic nature, unlike the very minor interactions seen between 
this amino acid and the ligands in the central site, which took the form of water bridges. There 
were also three interactions for (S)-citalopram that would fall into the previously labeled 
moderate interaction category, these are ALA331, PHE556 and GLU494 in order of the degree 
of interaction. Both ALA331 and PHE556 had solely hydrophobic interactions with the ligand, 
their interaction values being approximately 0.45 and 0.39 respectively. GLU494 has an 
interaction value of about 0.3, making it on the low side for a moderate interaction. The 
interactions GLU494 had with (S)-citalopram were made up of H-bonds, water bridges and 
ionic interactions, making it the most varied interaction for (S)-citalopram in both the central 
and allosteric sites. Amino acids that had a high to moderate degree of interaction with (S)-
citalopram in the allosteric site can all be seen to be within 3Å of the ligand in the system 
workspace at the end of the simulation (Figure 13 (C)). 
The simulation of serotonin in the allosteric site showed two amino acids that had a high degree 
of interaction, these were GLU494 and ASP328 in order of degree of interaction. GLU494 had 
an interaction value of about 1.1, with the interaction types being split between H-bonds, water 
bridges and ionic interactions, the H-bonds being the most common by a significant margin.  
ASP328 had an interaction value slightly above 0.8, as with GLU494 this interaction was also 
mostly H-bonds, with a small portion being made up of water bridges. There are a further three 
amino acids that can be labeled as moderate interactions, these are ALA331, PHE335 and 
GLU493. ALA331 had an interaction value slightly above 0.5 with the majority of the 
interactions being of the hydrophobic variety and a very small portion being H-bonds with the 
ligand. The second of the moderate interactions is PHE335, with an interaction value of about 
0.4, with the entirety of its interactions being hydrophobic. The last of the moderate interactions 
is GLU493 with an interaction value of about 0.35, which similar to GLU494, has its 
interactions split between H-bonds, water bridges and ionic interactions, with their relative 
quantity in that respective order. As can be seen from Figure 13 (D) the high interaction amino 
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acids GLU494 and ASP328 are within a 3Å range of the ligand at the end of the simulation, so 
are the moderate interaction amino acids ALA331 and PHE335. The moderate interaction 
amino acid GLU493 is however not within 3Å of the ligand at the end of the simulation. 
 
Figure 13: The above figure displays the Schrodinger Maestro workspace containing each 
respective MD simulation ligand and any amino acids that where within 3Å of the ligand in the 
allosteric site at the end of the 200 ns simulation. (C) is for (S)-citalopram and (D) is for 
serotonin. Color coding of atoms: red; oxygen, blue; nitrogen, green; ligand carbon atoms, 
gray; amino acid carbon atoms, white; hydrogen atoms. 
51 
 
4.1.2.2 Protein-Ligand Contact – Frequency and Quantity 
The figures below give a timeline representation of the interactions and contacts (H-bonds, 
Hydrophobic, Ionic, Water Bridges) that were presented in the 4.1.2.1 Protein-Ligand Contact 
– Binding Type section of the results. 
 
Figure 14: The above figure shows the quantity of contacts and frequency of contacts between 
the ligand and the protein over the course of the simulation in each of the four MD simulations 
that were run. The top row shows the MD simulations of the central site, with (A) (S)-
citalopram being on the left and (B) serotonin being on the right. The bottom row shows the 
MD simulations of the allosteric site, with (C) (S)-citalopram being on the left and (D) 
serotonin being on the right. Each part of the figure is itself divided in two between number of 
contacts over time, top, and frequency of individual amino acid contacts over time, bottom. 
The top part of the figure displays the total number of contacts (Y-axis) between the ligand and 
the protein over the course of the simulation (X-axis). The bottom part of the figure displays 
the contacts between individual amino acids belonging to the protein and the ligand (Y-axis) 
over the course of the simulation (X-axis). The color of the lines indicating a contact between 
the amino acid and the ligand is color coded using the scale (# of contacts) on the right side of 
the figure. The type of contact the amino acids had with the ligand can be seen in the 
corresponding Protein-Ligand Binding Type figure (Figure 11). 
 
The knowledge of the frequency of contacts between an amino acid and the ligand as well as 
the number of contacts between the ligand and amino acid at each registered point in time is 
invaluable for gaining greater insight into the specific interactions of the ligand within the 
binding site. The total number of interactions with the ligand also gives insight into the number 
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of amino acids that are holding the ligand in place and preventing it from drifting out of the 
binding site. From Figure 11 it was clear that TYR95 was a very important amino acid for the 
ligands in the central site, but from Figure 14 it became clear that not only was the interaction 
maintained with few gaps for the entirety of each central site simulation, but maintained with 
a significant degree of multiple simultaneous interactions. Interactions that were steadily 
maintained suggest that the interactions were quite stable, possibly holding the ligand in place. 
For (S)-citalopram in the central site in addition to TYR95 there were also ILE172 and 
TYR176, which maintained steady contact with the ligand for the majority of the simulation. 
While serotonin in its central site simulation had very steady contacts throughout the simulation 
with both ASP98 and SER438, in addition to TYR95 which was shared for both the central site 
simulations. 
For the allosteric site the only amino acid that (S)-citalopram maintained a steady near 
uninterrupted connection to was PHE335, with ALA331 having a fairly steady rate of 
interactions over the course of the simulations as well. PHE556 and GLU494 had steady 
interactions with (S)-citalopram for portions of the simulation, with PHE556 being in the first 
55 ns and GLU494 being between roughly 70 ns and 150 ns. PHE335 and ALA331 had the 
highest and second highest interaction scores respectively in Figure 11, which reflects on their 
steady interaction rates. With serotonin in the allosteric site there was a steady near 
uninterrupted interaction with GLU494, ASP328 also had a steady near uninterrupted 
interaction with serotonin from roughly the 75 ns mark. ALA331 had a steady interaction with 
serotonin from about the 85 ns point in the simulation. PHE335 which had a very strong and 
steady interaction with (S)-citalopram in the allosteric site had a fairly steady but sporadic 
interaction with serotonin, the connection being stronger in the early stages of the simulation. 
Figure 14 also shows the number of interactions that each ligand maintained over the course of 
the simulations, giving further insight into the interactions of the binding site. By comparing 
the central site (Figure 14 (A) & (B)) total contacts over time with those of the allosteric site 
(Figure 14 (C) & (D)) it appears that the central site on average maintains about one more 
contact on average throughout the simulation with the ligand than the allosteric site does. When 
comparing the ligands with one another it appears that (S)-citalopram (Figure 14 (A) & (C)) 





4.1.2.3 Protein-Ligand Contacts – Contact Strength 
Below figures display contacts that had maintained a contact strength of a minimum of 30% 
for the duration of the simulation. 30% was the standard setting used by the Simulation 
Interaction Diagram, and indicates the number of interactions that were maintained between 
contacts and for what degree of the simulation they were maintained. 
 
 
Figure 15: The figure displays the contacts between amino acids and the ligand for each of the 
MD simulations. For a contact to be displayed it was required to have a contact strength above 
the standard threshold of 30%. The top part of the figure displays the results from the central 
binding pocket, with (A) being (S)-citalopram and (B) being serotonin. The bottom part of the 




As can be seen from Figure 15 each of the ligands were under the effects of solvent exposure 
throughout the simulation, a contributing factor to the water bridge interactions that were 
observed to have occurred between the ligands and some amino acids in Figure 11. With 
regards to the amino acids that each ligand is shown to have a contact strength of above 30% 
within each respective binding site it is clear that the amino acids that were prominent in Figure 
11 and Figure 14 are also represented in Figure 15. For the (S)-citalopram in the central site we 
see TYR95, ILE172 and TYR176. Of particular note here is the interactions between TYR95 
and the NH+ of (S)-citalopram, showing which part of the antagonist is interacting most 
strongly with the central binding site. For serotonin in the central site we see a larger number 
of contacts that are above the 30% contact strength threshold (Figure 15). First among these 
are TYR95, ASP98 and SER438, which Figure 11 and Figure 14 clearly show have strong and 
steady connections with serotonin. TYR95, ASP98 and SER438 all interact with NH3
+, 
indicating that the interactions of NH3
+ with the central site are of significant importance. 
SER438 also has an interaction with the OH group of serotonin. NH3
+ is also seen to interact 
with SER336, although Figure 14 shows that this interaction is steady, but with regular gaps. 
ILE172 was present above the 30% contact strength threshold for both central site simulations, 
with Figure 11 showing that the interactions it had with the respective ligands was of a 
hydrophobic nature. 
The allosteric site simulation with (S)-citalopram had only PHE335 and ALA331 meeting the 
30% contact strength threshold (Figure 15). Figure 14 did also show quite clearly that there 
were very few amino acids in the allosteric site that maintained steady interactions with (S)-
citalopram for longer stretches of the simulation. The allosteric site serotonin simulation saw 
three amino acids meet the 30% contact strength threshold. First among them being GLU494 
which interacted with NH3
+ on serotonin, a contact that was heavily favored for serotonin in 
the central site. Second is ASP328, which interacted with NH on serotonin, a contact that was 
not seen in the central site above the 30% contact strength threshold. The final amino acid for 
serotonin in the allosteric site is ALA331, which was present for both allosteric site ligands 
above the 30% contact strength threshold. As was seen in Figure 11 the interactions from 
ALA331 were of a hydrophobic nature, although for serotonin there was also a small portion 





4.1.2.4 Central Site – amino acid movements 
In order to study the behavior of the amino acids of the central binding site measurements of 
the distance between selected amino acids were made. The amino acids that were selected are 
known to be crucial to the function of SERT (TYR95 (TM1), ASP98 (TM1), ILE172 (TM3), 
ASN177 (TM3), PHE341 (TM6), SER438 (TM8)) and are all part of the central binding site. 
The measurements that were made were between amino acids that were opposite to one another 
with the ligand between them, each pair had the measurements made between different 
transmembrane helices. The atoms that were selected to be used for measurements were 
selected oxygen or nitrogen side chain atoms facing the center of the binding site at the start of 
the simulation. In this fashion three measurements were made that together give some insight 
into the movements of these key amino acids relative to one another over the course of the 
simulations (Figure 16-18).  
 
Figure 16: The figure displays distance measurements made for all four MD simulations, 
measuring the distance between the amino acids TYR95 and ASN177 over the course of each 
respective simulation. The TYR95 amino acid is located in TM1 and ASN177 is located in 
TM3. The top row shows the MD simulations of the central site, with (A) (S)-citalopram being 
on the left and (B) serotonin being on the right. The bottom row shows the MD simulations of 
the allosteric site, with (C) (S)-citalopram being on the left and (D) serotonin being on the right. 
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From Figure 16 it can be seen that there were some differences between the simulations when 
looking at the distance between the TYR95 and ASN177 amino acids over time. Of particular 
note among these measurements are those for (S)-citalopram in the central site (Figure 16 (A)) 
and serotonin in the allosteric site with an empty central site (Figure 16 (D)). The simulation 
with (S)-citalopram in the central site appeared to be the one which had the greatest degree of 
instability in terms of distance between the measured amino acids. The simulation with 
serotonin in the allosteric site is however notable because the slowly rising distance between 
the measured amino acids for the first ~75 ns of the simulation, the somewhat stability 
displayed during the next 75 ns, then a slow slight decrease in average distance.  
 
Figure 17: The figure displays distance measurements made for all four MD simulations, 
measuring the distance between the amino acids ASP98 and PHE341 over the course of each 
respective simulation. The ASP98 amino acid is located in TM1 and PHE341 is located in 
TM6. The top row shows the MD simulations of the central site, with (A) (S)-citalopram being 
on the left and (B) serotonin being on the right. The bottom row shows the MD simulations of 
the allosteric site, with (C) (S)-citalopram being on the left and (D) serotonin being on the right. 
 
From Figure 17 it can be seen that the measured distances between ASP98 and PHE341 
contained significantly more fluctuations then the measured distances between TYR95 and 
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ASN177. Which in Figure 17 actually makes (A) unique in that it does not contain numerous 
maintained spikes in fluctuation. Rather the amino acids seem to be continuously fluctuating 
more than for the other simulations, the only area that can be described as a maintained spike 
in activity for (A) is the area between 80 ns and 160 ns, which appears to be a small lengthy 
spike in distance between the two amino acids. In addition to this the approximate average Å 
distance that is maintained is about 1.5 Å higher than for the other simulations, lying at 15.5 Å 
– 17.0 Å. The simulation with serotonin in the central site (B) may be the simulation with the 
most stable fluctuations in distance, even considering the two small and two tiny maintained 
spikes in activity. When not spiking in distance the distance between the amino acids fluctuates 
at a very stable 13-14 Å, which is quite stable when compared with the other sections of Figure 
17. 
For the two simulations with no ligand in the central site and (S)-citalopram (C) and serotonin 
(D) in the allosteric site the most notable feature of their distance measurements is the very 
numerous maintained spikes in distance. Both these simulations started with a substantially 
lower distance between the amino acids than for the central site simulation, but they quickly 




Figure 18: The figure displays distance measurements made for all four MD simulations, 
measuring the distance between the amino acids ILE172 and SER438 over the course of each 
respective simulation. The ILE172 amino acid is located in TM3 and SER438 is located in 
TM8. The top row shows the MD simulations of the central site, with (A) (S)-citalopram being 
on the left and (B) serotonin being on the right. The bottom row shows the MD simulations of 
the allosteric site, with (C) (S)-citalopram being on the left and (D) serotonin being on the right. 
 
From Figure 18 the distance between amino acids ILE172 and SER438 were measured over 
the course of each simulation. These measurements are notably between TM3 and TM8, while 
the measurements in Figure 16 and Figure 16 are both from TM1 towards respectively TM3 
and TM6. The central site simulation with (S)-citalopram is notable for the continuous large 
fluctuations that occurred for the majority of the simulation, fluctuating between 11-15 Å. This 
is in contrast to the simulation with (S)-citalopram in the allosteric site, where the measured 
distance between the amino acids is at its highest 12.5 Å and it goes as low as 8 Å. The allosteric 
site simulation had smaller fluctuations, although it did have some maintained spikes in 
measured distance. Both simulations with serotonin are comparatively more stable, with no 
large maintained spikes in distance and the fluctuations in measured distance between the 
amino acids staying in the range of about 2 Å between 10-12 Å. There does appear to be a 
slight trend towards the distance shortening from the 150 ns point, but an extended simulation 
would have been required to ascertain this. 
 
4.2 Induced Fit Docking of Experimentally verified Inhibitors 
Inhibitors were selected from a previous study in our research group (100), all selected 
inhibitors (apart from citalopram) had been experimentally verified in that paper. Inhibitors 
had also been run through a virtual screening using a SERT outward-facing homology model. 
4.2.1 Docking Score 
The most promising inhibitory compounds were selected from among structurally based 
clusters in the paper, if a cluster had no compounds of sufficient quality it would not be taken 







Table 1: The table shows the results of the docking of selected inhibitory compounds 
previously tested in an earlier study in our research group (100). The ID refers to the 
compounds ID number, which is used to identify a compounds name in the Appendix 
(Appendix Table 1). The Structure PDB ID is the crystal structure the inhibitory compound 
was docked into, the Site refers to which binding site within the crystal structure it was docked 
into, either Central or Allosteric. The Docking Score is the score the ligand got when docked 
into the docking site, scores below -6.0 are acceptable, lower is better. Ranking refers to the 
compounds Docking score relative to the other docked compounds.  
Structure ID Structure  
PDB ID 
Site Docking Score Ranking 
 
1 5I71 Central -8.56 
18/32 
1 5I73 Allosteric -8.02 
22/32 
 
2 5I71 Central -8.99 15/32 
2 5I73 Allosteric -7.11 30/32 
 
3 5I71 Central -9.89 
9/32 
 
3 5I73 Allosteric -7.63 
27/32 
 
4 5I71 Central -11.05 
2/32 





5 5I71 Central -9.44 
12/32 
 
5 5I73 Allosteric -7.52 
28/32 
 
6 5I71 Central -7.95 
24/32 
6 5I73 Allosteric -6.19 
32/32 
 
7 5I71 Central -8.34 
19/32 
7 5I73 Allosteric -6.86 
31/32 
 
8 5I71 Central -10.24 5/32 
8 5I73 Allosteric -7.33 
29/32 
 
9 5I71 Central -9.85 
10/32 
9 5I73 Allosteric -7.99 
23/32 
 
10 5I71 Central -10.13 
7/32 
 





11 5I71 Central -12.10 
1/32 
 
11 5I73 Allosteric -8.77 
16/32 
 
12 5I71 Central -9.58 
11/32 
 
12 5I73 Allosteric -7.79 
25/32 
 
13 5I71 Central -10.13 
7/32 
 
13 5I73 Allosteric -7.65 
26/32 
 





14 5I73 Allosteric -8.32 
20/32 
 
15 5I71 Central -10.93 
3/32 
15 5I73 Allosteric -9.01 
14/32 
 
16 5I71 Central -10.58 
4/32 
 




The induced fit docking of the experimentally verified inhibitors alongside citalopram provided 
a large quantity of data relating both which amino acids the compounds interacted with in their 
best scoring poses (Appendix Figure 1-8) and also how the compounds scored between the 
binding sites comparatively. The compounds were ranked according to docking score, as can 








4.2.2 Docking Score – Statistical Analysis 
Here we look at what the data gained from the induced fit docking part of the study can yield 
when analyzed statistically. The sample small size is limiting, with only 15 experimentally 
tested inhibitors being used, the results are also potentially significantly influenced by outliers.  
 
 
Figure 19: The figure displays the docking scores for each of the experimentally verified 
compounds, the score for the central site is along the X-axis and the score for the allosteric site 
is along the Y-axis. There was found to be a correlation equal to 0.8074 between the docking 
scores of the central site and the allosteric site. 
 
When comparing the docking scores of each compound between the central site and the 
allosteric site (Figure 19) it became clear that there was a high positive correlation, specifically 
a value equal to 0.8074, between the scores of the respective sites for each compound. From 
the plot, it is seen that a compound will have a higher docking score in the central site than in 
the allosteric site. The average docking score in the central site is -9.827 and -7.879 for the 




Figure 20: The figure above displays the docking scores for all the experimentally verified 
compounds in the central site (left) and allosteric site (right) against the experimental Ki 
(Appendix Table 1) that was found for the compounds in the experimental study (100). The 
docking score is along the X-axis and the experimental Ki is along the Y-axis. There was found 
a correlation equal to -0.0749 for the central site and of size 0.0042 for the allosteric site.  
 
This data in Figure 20 indicates that there is neither a linear relationship between the docking 









Figure 21: The figure above displays the docking scores for all the experimentally verified 
compounds in the central site (left) and allosteric site (right) against the inhibition in percentage 
(Appendix Table 1) that was achieved for the compounds in the experimental study (100) with 
the Ki listed in (Appendix Table 1). The docking scores is along the X-axis and the inhibition 
percentage the compound achieved is along the Y-axis. There was found to be a correlation 
equal to 0.2548 for the central site and a correlation of -0.0298 for the allosteric site.  
 
For the central site (Figure 21, right) there was found to be a small degree of correlation 
between the docking score of the compound and its inhibition percentage. However, given the 
small sample size the degree of correlation that was found may in fact not be significant. For 




4.2.3 Amino Acid interactions of docked compounds 
The compounds that were docked during the docking study also provide data through the 
location of the ligand in their best scoring docking pose. Specifically, by looking at which 
amino acids, and ions, the ligand may or may not have interacted with while in each respective 
binding site. For the central site there are numerous amino acids that are known to be crucial 
to the function of SERT, but for the recently discovered allosteric site the amino acids that are 
interacted with may give insight into the specific interactions that would occur in the allosteric 
site of SERT in vitro. 
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Table 2: The table shows the interactions between each respective ligand and the amino acids 
of the central site. The interactions were obtained from the Ligand Interaction Diagram using 
the default settings (See Appendix Figure 1-4). The numbers in the first row designate each 
compounds ID, the leftmost column designates the interacting molecule. An X indicates if there 
was an interaction listed in the Ligand Interaction Diagram between the respective ligand and 
the molecule listed in the leftmost column. 
Interactions Ligand 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
TYR95 X X X X X X X X X X X X X X X X 
ALA96 X X X  X X X X X X X X X X X X 
VAL97   X  X        X X  X 
ASP98  X X X X X X X X X X X X X X X 
GLY100   X              
ARG104   X          X    
ILE168     X     X   X X   
ALA169 X X X X X X X X X X X X   X X 
ILE172 X X X X X X X X X X X X X X X X 
ALA173  X X X X X X X X X X X X   X 
TYR175    X      X  X  X X X 
TYR176 X X X X X X X X X X X X X X X X 
ASN177  X X X   X    X      
MET180    X       X      
PHE334     X X  X X  X X  X   
PHE335 X X X X X X X X X X X X X X X X 
SER336 X X X X X X X X X X X X X X X X 
LEU337 X X X  X   X  X X X X X X X 
GLY338 X X X X X X X X X X X X X X X X 
PRO339        X   X   X   
PHE341 X X X X X X X X X X X X X X X X 
VAL343      X  X   X    X  
ASN368   X           X   
GLY435    X             
SER438 X X X X X X X X X X X X X X X X 
THR439 X X X X X X X X X X X X X  X X 
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GLY442 X X X X X X X X X X X X X  X X 
LEU443  X X X X X X X X X X X    X 
VAL446           X      
GLU493    X        X  X   
THR497    X      X  X  X X X 
GLY498    X        X  X X X 
VAL501 X  X X X X X X X X X X X X X X 
NA707  X X X X X X X X X X X X X X X 
 
As can be seen from Table 2 there are numerous amino acids and one ion that the ligands tend 
to interact with in the central site. There are however some of these interactions which occur 
on a consistent basis with all or nearly all the ligands. The molecules that are seen to interact 
with the ligand in each or all but one case are; TYR95, ALA96, ASP98, ILE172, TYR176, 
PHE335, SER336, GLY338, PHE341, SER438, THR439, GLY442, VAL501 and NA707. 
When it comes to amino acids that are known to be crucial to the function of SERT these are 
TYR95, ASP98, ILE172, ASN177, PHE341 and SER438 (118). Among the molecules that 
interact with the ligand in all but one case five out of the six amino acids that are known to be 
crucial for the function of SERT are included, with the final amino acid ASN177 having 












Table 3: The table shows the interactions between each respective ligand and the amino acids 
of the allosteric site. The interactions were obtained from the Ligand Interaction Diagram using 
the default settings (See Appendix Figure 5-8). The numbers in the first row designate each 
compounds ID, the leftmost column designates the interacting molecule. An X indicates if there 
was an interaction listed in the Ligand Interaction Diagram between the respective ligand and 
the molecule listed in the leftmost column. 
Interactions Ligand 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
TYR95   X       X     X  
ALA96          X     X  
ASP98   X X      X  X   X  
GLY100    X       X   X  X 
ASN101    X             
ARG104 X X X X X X X X X  X X X X  X 
ILE108      X X X   X     X 
ALA169          X     X  
ILE172   X  X     X  X  X X  
ALA173          X       
TYR175 X  X  X   X X   X  X X  
TYR176   X       X  X   X  
ILE327      X X    X  X   X 
ASP328      X X    X     X 
ALA331 X X  X X X X X X  X X X X  X 
GLN332  X  X  X X    X  X X  X 
PHE335 X X X X X X X X X X X X X X X X 
SER336    X      X X   X X  
LEU337          X     X  
GLY338   X       X     X  
PHE341   X       X     X  
SER438   X       X     X  
THR439          X     X  
GLY442          X     X  
LEU443          X       
LYS490        X         
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GLU493 X X X X X X  X X  X X X X X X 
GLU494 X X X X X X X X X  X X X X  X 
TYR495  X   X            
THR497   X  X   X X   X  X   
GLY498 X X X X X X X X X X X X X X X X 
PRO499 X X X X X X X X X  X X X X  X 
VAL501   X       X  X     
LEU502 X X X X X X X X X  X X X X  X 
ILE552 X X  X X X X X X  X X X X  X 
ILE553       X X X   X     
SER555           X  X    
PHE556 X X  X X X X X X  X X X X  X 
SER559             X    
PRO561  X   X X  X X  X X X   X 
NA707    X           X  
 
As can be seen from Table 3 there are numerous amino acids and one ion that the ligands tend 
to interact with when docked into the allosteric site. As with the central site there are some of 
these amino acids that that tend to interact with the ligands more consistently than others. The 
specific amino acids that tend to interact with the ligands are also, for the most part, different 
from the central site. Something in part caused by the approximate distance of 13 Å between 
the central and allosteric binding sites. Using the same parameters as with the central site for 
selecting molecules that interact with the ligand in all or all but one case gives us only the 
amino acids PHE335 and GLY498 that all ligands interacted with when docked into the 
allosteric site. If we however adjust the parameters for selecting high interaction rate amino 
acids to discount for ligands 3, 10 and 15 we find that the following amino acids now meet the 
updated requirements; ARG104, ALA331, PHE335, GLU493, GLU494, GLY498, PRO499, 
LEU502, ILE552 and PHE556. Among these there are no amino acids that are known to be 
crucial to the function of SERT, although the same study did find that mutations to PHE335 
did give a significant reduction to the transport activity of SERT (118). 
Ligands 3, 10 and 15 are, as can be seen from Table 3, in many ways outliers that interact with 
amino acids that other ligands docked in the allosteric site did not interacts with. The most clear 
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and notable examples is TYR95, which is an amino acid that all ligands in the central site 
interacted with (Table 2). The optimal placement by the IFD protocol of each of these ligands 
in the workspace is responsible for this, having placed them in the area between the central and 
























4.3 Experimental testing of potential GABAB receptor antagonists 
For the experimental portion of the project, ten compounds were selected from an ongoing 
study (Evenseth et al. 2018, unpublished work) and their activities were tested towards the 
GABAB receptor using a cAMP functional assay. This experimental screening was first tested 
on a CHO-K1 Wild Type cell line to determine if the compounds would interact with any 
receptors other than the GABAB receptor. The initial screening then tested the compounds 
against a CHO-K1 cell line stably expressing the GABAB receptor in order to investigate if the 
compounds had any direct effect on the GABAB receptor. The compounds being tested 
experimentally had been selected based on their scoring in an in silico virtual screening 
approach for antagonists of the GABAB receptor. The results included in this project are for 
only a single run of the assay, not a triplicate run. Numerous delays and malfunctioning 
equipment pushed the schedule for performing the assay back so far that it was no longer 
feasible to perform a triplicate of the assay within the projects timeframe. Due to this, the results 
of the assay are not totally reliable as the lack of triplicate testing leaves significant room for 
error at multiple stages. 
The need for two solvents, and therefore two controls, for the test compounds came from the 
low solubility of five of the compounds. Specifically compound 2, 3, 6, 8 and 9 were not soluble 
in the standard assay buffer HBSS and required a different more soluble solvent, a D-glucose 
solution, referred to as 5G. The soluble compounds were 1, 4, 5, 7 and 11, all of which were 





Figure 22: The above bar chart shows the results of the functional cAMP assay to test the ten 
selected compounds against a CHO-K1 Wild Type cell line in order to determine if the 
compounds had any effect on the receptors of the native Wild Type cells. The X-axis shows 
the contents of the tested wells, with the two columns on the left being the controls and the ten 
on the right being the compounds that were being tested. The Y-axis shows the relative light 
unit (RLU) of each well that has a linear relationship to the cAMP expression level. Each well 
was done in triplicate during the assay and the above results shows the average, with the 
standard deviation displayed on top of each column. The dotted line was set to the average of 
the control (stimulation of 30 µM forskolin alone). 
 
Test compounds’ activity against CHO-K1 WT is shown on Figure 22. The two leftmost 
columns are the controls, one for each solvent of the respective compounds. As can be seen 
from Figure 22 the 30 µM FSK 5G control was clearly anomalous, as it was supposed to be of 
equal level with the 30 µM FSK 2xHBSS control. It was therefore decided to use the 30 µM 
FSK 2xHBSS as a baseline to see if any of the compounds displayed irregular activity. As the 
bar chart in Figure 22 is on an individual assay, the results are less certain with more room for 
the effects of experimental errors. However, compared to the forskolin control and their 
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standard deviation, three compounds (compound 1, 2 and 8) showed a higher cAMP level than 
the rest of the compounds. This might indicated that compound 1, 2 and 8 interacted with an 
endogenous receptor or another cell component in the WT CHO-K1 cells. 
 
Figure 23: The above bar chart shows the results of the cAMP assay to test the ten selected 
compounds against a CHO-K1 cell line expressing the GABAB receptor in order to determine 
if the compounds had an inhibitory effect on the GABAB receptor. The X-axis shows each the 
contents of the tested wells, with the two columns on the left being the controls and the ten on 
the right being the compounds that were being tested. The Y-axis shows the relative light unit 
(RLU) of each well that has a linear relationship to the cAMP expression level. Each well was 
done in triplicate during the assay and the above results shows the average, with the standard 
deviation displayed on top of each column. The dotted line was set to the average level of the 
controls (stimulation of 1 µM GABA + 30 µM forskolin).  
 
The second assay performed was to test if the chosen compounds showed any reaction with the 
GABAB receptor transfected cell line. A reaction in this cell line would indicate that the 
compound interacted with GABAB receptor in an agonistic or antagonistic manner, if there was 
no similar reaction from the compound in the wild type cell line. As can be seen from Figure 
23 the only compound that has a higher RLU was compound 1, but compound 1 also showed 
a similar degree of interaction during the wild type assay. This raises the possibility of 
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compound 1 reacting with the cell through a different pathway than the GABAB receptor. The 
other compounds showed RLUs close to that of the controls, indicating there was potentially 
no inhibitory reaction. The compounds with lower RLUs than controls may indicate agonist 
like activity against the GABAB receptor. Compounds 2, 3 and 6 showed the strongest agonist-
like activity, at least three repeated individual assays are needed to confirm that the observed 
activity is not caused by experimental error. 
Table 4: The below table shows an overview of the data from Figure 22 and Figure 23. The 
leftmost column shows the compound IDs and name of controls for each respective row. The 
solubility column shows if the compound had a high or low solubility. Compounds with high 
solubility were dissolved in the assay buffer (HBSS), compounds with low solubility were 
dissolved in the 5G buffer. The following columns displays the percentage value for each of 
the bars in the bar charts of Figure 22 and Figure 23 in comparison to the non-anomalous 
controls. For the WT assay all compounds are compared with the assay buffer control, 
including the 5G buffer control which was anomalous. For the GABAB assay the high solubility 
compounds are compared with the assay buffer and the low solubility compounds are compared 
with the 5G buffer. For both of these assays each rows standard deviation is also listed in 
percentage. 












1 High 111.73 ± 2.14 92.17 ± 2.69 
2 Low 116.90 ± 2.56 120.95 ± 1.25 
3 Low 104.31 ± 3.75 119.76 ± 7.39 
4 High 109.28 ± 1.13 105.76 ± 6.83 
5 High 101.39 ± 5.81 104.13 ± 3.53 
6 Low 104,37 ± 3.84 122.54 ± 3.21 
7 High 109.48 ± 2.12 107.02 ± 3.12 
8 Low 124.72 ± 2.55 103.12 ± 2.41 
9 Low 106.89 ± 1.36 108.56 ± 1.50 
11 High 89.86 ± 2.98 103.24 ± 3.24 
30 µM FSK 
2xHBSS 
(Control - High) 
 100 ± 2.77 100 ± 1.80 
30 µM FSK 5G 
(Control - Low) 




The bar charts of Figure 22 and Figure 23 do not provide exact values for their columns, but 
do provide a good comparative overview between the controls and different compounds. For a 
more exact overview there is Table 4, which has all the values listed as a percentage value of 
that of the controls. As the low solubility buffer (5G) was anomalous in the WT assay it was 
not used for comparative purposes. The anomalous nature of the WT 5G buffer control is clear 
from its very low comparative value with that of the other control and all the compounds. 























5.1 Molecular Dynamics 
The four MD simulations that were performed for this project were 200 ns in length. This 
makes the MD simulations unsuitable for the study of changes to the overall structure of the 
protein, but allows the project to instead focus more closely on the interactions between the 
ligand and the protein over the course of the simulation. It also permits closer study of the 
behavior of amino acids in the central that are known to be crucial for the function of SERT 
(118). The analysis of the projects MD simulation results shall therefore be focused on the 
interactions of the respective ligands in both binding sites, and also on how these ligands affect 
the above mentioned crucial amino acids located in the central site. 
 
5.1.1 Structural Stability 
While the simulations that were performed for the project are too short to study potential 
changes to overall protein structure it is still important to ascertain that the protein structures 
were stable throughout their simulations. The Protein RMSD observable in Figure 9 is 
indicative of the protein structures being stable in each simulation after a short adjustment 
period at the start of the simulation. Each simulation shows that the movements of the protein 
structures relative to the reference frame backbone are highly stable, with no fluctuations 
exceeding 0.5 Å after the initial 50 ns of the simulation. The Ligand RMSD on the other hand 
is more variable between simulations, but all the ligands do stabilize before the 100 ns point of 
the simulation with no ligand having left its binding site. The Protein RMSF observable in 
Figure 10 shows that there are similar movements between amino acids in each protein 
structure over the course of the simulations, although there are some amino acid movement 
degrees that differ slightly from one another along the lines of which binding site was used. 
The difference is either caused by the use of different crystal structures between the central site 
simulations and the allosteric site simulations, or potentially the placement of the ligand may 






5.1.2 Ligand Interactions 
The interactions between the ligands, (S)-citalopram and serotonin, and the binding sites for 
each simulation provided a lot of data regarding what amino acids interact with each ligand, 
the type of interaction and also to what degree they interact. The analysis of the simulation 
trajectory data allows insight into the complex interactions that occur within the central and 
allosteric binding sites of SERT with both the native substrate present and a well-tolerated 
SSRI (13).  
 
5.1.2.1 Central Site 
There have been previous computational studies (54) that studied SERT through the use of MD 
simulations, but these simulations were for only the central binding site using a homology 
model. With the use of a crystal structure there is a higher degree of certainty that the protein 
structure in the model system is reflective of what the actual structure of SERT is, especially 
in areas greatly affected by structural shifts such as binding sites. 
As was described in the results section there were a total of six amino acids that passed the 
30% contact strength threshold (Figure 15) within the central site. Two of these, TYR95 and 
ILE172, were shared for both ligands as high strength contacts. TYR176 was the third high 
contact strength amino acid for (S)-citalopram, but for serotonin it was a minor hydrophobic 
influence (Figure 11 (B)). Something which suggests that TYR176 perhaps plays a minor role 
within SERT for the transport of its substrate serotonin, but plays a more important role for the 
binding of an inhibitor. Further computational studies using an inhibitor other than (S)-
citalopram would be able to investigate this further. The other three high contact strength amino 
acids that interacted with serotonin were ASP98, SER336 and SER438. Of these ASP98 was 
also shared with (S)-citalopram, although it had an interaction value of about 0.15 compared 
to serotonins value of 1.0, given its proximity to TYR95 within the central binding site any 
ligand that interacts with TYR95 would probably have some interactions with ASP98 as well. 
For the last two amino acids, SER336 and SER438, they were listed in Figure 11 (A), indicating 
that the ligand had at least one interaction with each of them over the course of the simulation, 
but the interaction value is very low. From Figure 14 one can see that (S)-citalopram had one 
and two points of interaction respectively for SER336 and SER438 over the course of the entire 
simulation. Such low interaction values with (S)-citalopram are indicative of the amino acids 
being substantially more important for serotonin than (S)-citalopram.  
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When comparing the amino acids that the ligands are interacting with in the central site with 
the six previously mentioned amino acids known to be crucial for SERT activity (TYR95, 
ASP98, ILE172, ASN177, PHE341, SER438), it can be seen (Figure 11 (A) and (B)) that only 
ASN177 does not interact with the ligands in the central site. With the exception of ILE172 it 
is also quite clear that serotonin, the substrate of SERT, interacts more strongly with all of these 
known crucial amino acids than (S)-citalopram.  
When looking at the nature of the interactions that are occurring throughout the central site 
(Figure 11 (A) and (B)) there is clear divide between (S)-citalopram which favors hydrophobic 
interactions and serotonin which has H-bonds as its favored interaction. Both ligands however 
have a similar ratio of hydrophobic to H-bond interactions with TYR95. Ionic interactions are 
the least common, with only a small portion of ASP98’ interactions being of an ionic nature 
for both ligands. The final interaction type is of particular interest as it deals with the dynamics 
of an MD simulation, water bridge interactions. As a water bridge interaction is a hydrogen-
bonded protein-ligand interaction mediated by a water molecule it is the movement of water 
molecules in the binding site that allows them to form between the ligand and various amino 
acids. Water bridges are less common interactions than H-bonds and hydrophobic interactions 
(Figure 11), but still make up a substantial number of protein-ligand interactions. A portion of 
the interactions with serotonin of the known crucial amino acid SER438 are water bridges. 
Other amino acids in the central site that formed water bridges with the ligand had this as their 
sole form for interaction with each respective ligand. For (S)-citalopram there were two amino 
acids, TYR175 and THR497, both of which had interaction values of about 0.1. Serotonin also 
had another two amino acids with exclusively water bridges with the ligand, these being 
PHE334 and GLY442. PHE334 had an interaction value of about 0.1, while GLY442 had an 
interaction value of about 0.2, making GLY442 the amino acid with the largest amount of water 









5.1.2.2 Allosteric Site 
Several in vitro experimental studies have indicated that inhibitors including citalopram could 
allosterically modify SERT activity (119), but the allosteric binding site was not firmly 
identified due to lack of detailed structural information. As the allosteric site of SERT was 
identified with the rendering of the crystal structure (53), the previous study of SERT using a 
homology model did not investigate it (54). With the allosteric site having not previously been 
investigated, any insights gained from the data regarding the interactions of the ligands in the 
allosteric site are potential avenues of further investigation. The 30% contact strength threshold 
is a good starting point for insight into the allosteric site, and the allosteric simulations provided 
a total of four amino acids that passed this threshold (Figure 15 (C) and (D)). Among these 
only ALA331 was included above the threshold for both the ligands. (S)-citalopram had 
PHE335 in addition to ALA331, while serotonin had ASP328 and GLU494. For both ligands 
ALA331 was a source of hydrophobic interactions with an interaction value of about 0.5 for 
both (Figure 11 (C) and (D)), although serotonin also did form some H-bonds with the amino 
acid. Both ASP328 and GLU494 had primarily H-bond interactions with serotonin, but they 
both also had a small portion of water bridges and GLU494 even had some ionic interactions. 
PHE335 was also a fairly prominent interaction for serotonin (Figure 11 (D)), even if it did not 
meet the 30% contact strength threshold. For both ligands it provided exclusively hydrophobic 
interactions, and while it was not a crucial amino acid, the mutational mapping (118) study did 
find that the mutation of PHE335 did have significant effects on the activity of SERT. With 
the mutational mapping study measuring SERT activity using a [3H]-serotonin uptake assay as 
a percent of activity of their WT cells it shows clearly that the various mutations of PHE335 
would give a significant reduction of SERT transport activity. The mutation of PHE335 also 
caused changes in (S)-citalopram potency in some cases (118), indicating that it does indeed 
play an important role for SERT during in vitro testing. A new mutational mapping study, this 
time focusing on the allosteric site, could have a look at some of the amino acids with higher 
interaction values (Figure 11 (C) and (D)). As the mutation of PHE335 did affect the overall 
activity of SERT it is possible that some of the other prominent amino acids in the allosteric 
site also play key roles in its activation process. Further computational studies could also yield 
greater insights, especially if longer MD simulations were performed in order to study potential 
structural shifts that could occur both for (S)-citalopram and for serotonin. If the simulation 
was substantially longer there would perhaps be a chance to see the ligand migrate from the 
allosteric site into the central site, such a migration would of great interest to study. Such a 
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migration is hypothesized to be possible (120), there are also indications for the presence of a 
ligand occupying the allosteric site being capable of blocking egress from the central site (53). 
The interactions occurring within the allosteric site were once more mostly hydrophobic for 
(S)-citalopram and mostly H-bonds for serotonin, indicating that each respective ligand may 
have a greater propensity for certain types of interactions. (S)-citalopram has five amino acids 
(Figure 11 (C)) with interaction values above 0.1 that were exclusively or near exclusively 
hydrophobic, with the only amino acid with a noteworthy interaction value and no hydrophobic 
interactions being GLU494. Serotonin has four amino acids (Figure 11 (D)) with interaction 
values above 0.1 that are exclusively or near exclusively hydrophobic, but serotonin has an 
additional five amino acids that it interacts with. Only one of these possessing a small portion 
of hydrophobic interaction with the ligand, and two of the others are ASP328 and GLU494, 
having the highest interaction values for serotonin and both being within the 30% contact 
strength threshold. Another notable difference in interactions between (S)-citalopram and 
serotonin is the relative amounts of water bridge interactions, with serotonin having both more 
amino acids with water bridge interactions, but also higher interaction values for those amino 
acids (Figure 11 (D)). A contributing factor to this disparity could be the fact that serotonin has 
substantially more contacts throughout the allosteric site for the duration of its simulation when 
compared with (S)-citalopram (Figure 14 (C) and (D)). If a future computational study were to 
be carried out with a focus on protein-ligand interactions in the allosteric site the use of multiple 
allosteric inhibitors would be of interest to study, if there is a general propensity for 
hydrophobic interactions among inhibitors or if this is a feature unique to (S)-citalopram. 
 
5.1.3 Central Site Amino Acid Movement 
The measurements of distance between amino acids in the central site gave some insight into 
the fluctuations of the central site as a consequence of ligand placement and if the ligand was 
the substrate or an inhibitor. The first thing to note here is that there clearly was a difference 
between the four simulations in regards to the fluctuations between these amino acids (Figure 
16-18), with some amino acid measurement pairs having more fluctuations than others. This 
means that the central binding site is affected by presence of a ligand, or lack thereof. If there 
was also performed a simulation for both crystal structures with no ligand in either site this 
would have been valuable in order to compare if the central site was affected by a ligand being 
in the allosteric site or simply from lack of a ligand in the central site. From the plots that were 
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made of the measurement data it is clearly possible to see that the movements are not identical 
between the simulations, but seeing if there is any significance hidden in the fluctuations would 
require a statistical model. The lack of a simulation without the presence of ligands in any of 
the binding sites as a control makes it so no certain conclusions can be drawn from these 
measurements other than that there is variation between each of the simulations. This is in itself 
an indication that the presence of the ligands may have an effect on the fluctuations of the 






















5.2 Induced Fit Docking of Experimentally verified Inhibitors 
The experimentally verified inhibitors that were selected for the docking portion of the study 
were all initially identified through a virtual screening approach (100). This virtual screening 
used the ligand-based methods, 2D fingerprinting and a 3D pharmacophore follow-up, in 
combination with a structural screening using a homology model of SERT (54) based on the 
LeuT crystal structure. The combined databases used for the virtual screening approach 
contained approximately 2.5 million compounds, the approach reduced this to 182 compounds 
that could then be selected to go on to the biological evaluation where they could be verified. 
The compounds made it through the virtual screening by having characteristics of known 
inhibitors for the ligand-based portion and for having good docking scores in the central site of 
the homology model for the structure-based portion. This in essence means that the compounds 
were in part selected for their high docking scores in the central site. It is therefore not very 
surprising that there was found to be a high positive correlation between a higher central site 
docking score and a lower allosteric site docking score (Figure 19). The correlation was equal 
to 0.8074, with a 1 meaning that the relationship would have been completely linear. An even 
more interesting observation is that the two docking scores are not very different. In fact, the 
average difference is only 1.948 lower for the allosteric site. Several related factors may 
contribute to this relationship between the docking scores of the allosteric and central sites. The 
first of these is that the pharmacophores that were developed for the ligand-based portion of 
the virtual screening were based on known substrates and inhibitors, some of which may have 
affected the allosteric site. The attributes of the compounds that affected the allosteric site 
would therefore be among the selecting factors during the ligand-based approach. The next 
factor relates to the structure of SERT and the proximities of the central and allosteric sites to 
one another. As these binding sites are quite close to one another, approximately 13 Å apart 
(53), it has been hypothesized that moving through the allosteric site is necessary to reach the 
central site (120). For a compound to be able to reach the central site it may therefore be 
necessary for it to have an affinity with the allosteric site above a certain threshold. Whichever 
may be the case there is however a strong correlation within this small sample group between 
high docking scores in the central site and lower docking scores in the allosteric site. 
Which brings us the experimental data of the compounds that were selected for the docking 
study. It should be stated first that given the complexity of the activation of a transporter protein 
and the many factors of molecular interactions, it was not expected to find a correlation between 
the docking scores of compounds and their experimental Ki. The mutation of a single amino 
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acid such as PHE335 can alter the Ki of (S)-citalopram by several fold, as an example of just 
one such factor. A docking score of a compound while placed in the optimal position found by 
the IFD protocol is therefore not going to find any linear correlation between a Ki and docking 
score (Figure 20). The primary reason to perform the analysis between these two values was to 
show that there would be found no correlation between them. Which brings us the next data 
that was investigated for correlation, the relationship between docking score by site and (%) 
inhibition of SERT. In modern drug development it would be an immense boon if there existed 
a direct relationship between a compounds docking score in an orthosteric site and its (%) 
inhibition of that protein. Any compound with a high docking score would have a high (%) 
inhibition if there was a correlation of 1 between these two values. There is however no such 
direct correlation, and this we can see in Figure 21. There is however a slight tendency for 
compounds with higher docking scores in the central site to have a higher (%) inhibition. While 
the small sample size is a limiting factor for giving this statistical significance, it is a weak 
indication that compounds with high docking scores may also provide a high (%) inhibition. 
The issue is complicated by the fact that it is unknown whether these compounds bind to the 
central or allosteric binding site to enact their inhibitory effect upon SERT.  The additional 
uncertainty this adds to the statistical relevance of even the small correlation that was found is 
therefore questionable. Nonetheless, there was found to be a small correlation between the 
central site docking scores of the experimentally verified compounds and their (%) inhibition 
for SERT at their optimal Ki. 
 
5.2.1 Central Site 
The interactions between the docked ligands and the central site were studied through the use 
of the Ligand Interactions Diagram (101), a part of the unified Maestro interface. The default 
settings were used to study which amino acids (S)-citalopram and each of the experimentally 
verified compounds interacted with in the central binding site (Appendix Figure 1-4). This data 
was then compiled into Table 2, where we have an overview of how many of the inhibitors 
interacted with each of the listed amino acids. As was mentioned in the results all but one of 
the crucial amino acids identified by a previous study (118) were found to interact with all or 
all but one of the inhibitors when docked into the central site. But there were also additional 
amino acids that were interacted with, amino acids that only saw small degrees of interactions 
with the ligands over the course of the MD simulations. These were ALA96, PHE335, 
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GLY338, THR439 and VAL501, which varied between small interactions with both central 
site ligands or no interactions with one of the ligands during the central site MD simulations. 
In the docking of SERT inhibitors they were however featured in every docking in the case of 
PHE335 and GLY338, and in all but one docking for the other three. This is indicative on these 
amino acids some effect on the optimal position of the ligand within the binding site. The 
mutational mapping study did investigate both PHE335 and THR439 for how they affected 
SERT activity, both of which significantly reduced SERT activity when mutated, with the 
degree of reduction varying between what amino acid they were replaced with. ALA96, 
GLY338 and VAL501 should be considered potential candidates for a mutational study to see 
how their mutation would affect SERT activity, alongside high interaction value central site 
amino acids from the MD simulation that have not been previously investigated. There was 
one additional molecule that was seen in all but one of the interaction overviews, the ion 
NA707. The importance of the Na+ ions for the initiation of the translocation process for SERT 
has not been strictly determined, but there are indications that they do play an important role 
in this (121). To investigate how the Na+ ion NA707 affected the docking scores of the 
compounds the dockings could be repeated without the presence of the two Na+ ions and with 
the ligands fixed in their previous optimal positions. 
 
5.2.2 Allosteric site 
The interactions of the docked ligands in the allosteric site (Appendix, Figure 5-8) were studied 
in the same manner as with the central site and the interactions were compiled into Table 3. 
This gives an overview of which interactions occur between the ligands and the binding site. 
For the allosteric binding site however, there were only two amino acids (PHE335 and 
GLY498) that interacted with every ligand. The reason for the relatively few amino acids that 
interacted with every ligand, or all but one, is the outliers mentioned in the results. A visual 
inspection of the positioning of ligand 3, 10 and 15 showed that they had managed to find an 
optimal docking position partially inside the central site. The proximity of the allosteric and 
central sites does make this possible, as the binding site for the docking is defined as an area 
within a three-dimensional box centered on the native allosteric site ligand (S)-citalopram’s 
position. By including amino acids that interacted with all or all but one ligands and removing 
the outliers, the amino acids that meet the updated criteria are now ten. Among these ten amino 
acids there were six (ARG104, ALA331, PHE335, GLU493, GLU494 and PHE556) that saw 
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small to large interactions with the ligands of the allosteric site simulations. The remaining four 
amino acids (GLY498, PRO499, LEU502 and ILE552) all saw negligible interactions 
throughout the simulations. The amino acids with negligible interactions may possibly not 
interact well in the allosteric site with the ligands that were used for the MD simulations. If 
additional simulations were carried out using the compounds of the docking study it would be 
seen if these ligands show a greater degree of interaction with some of the amino acids that had 
less interactions during the two allosteric site simulations. The disparity between (S)-
citalopram and serotonin in terms of amino acids interacted with indicates that a wider set of 
ligands for MD simulations would perhaps have uncovered additional amino acids that showed 
high interaction values.  
If a mutational study of the allosteric site was to be carried out, as mentioned in the MD 
simulations discussion, it would perhaps be of interest to include the amino acids found to have 
interactions with the majority of ligands docked as candidates. Although the above mentioned 
further MD simulations could first be carried out to attempt to uncover signs further indicating 
the importance of individual amino acids as way to narrow the number of amino acids that 
would be included in such a study. The additional MD simulations would also serve to reinforce 
the importance of any amino acid that is frequently seen to interact significantly over the course 
of the respective MD simulations. Using the mutational mapping study (118) as a backdrop it 
would also be interesting how the mutations they applied would affect an in silico model system 
of SERT. The mutation of the crucial amino acids would perhaps lead to the complete 












5.3 Experimental testing of potential GABAB receptor antagonists 
The potential GABAB receptor antagonists that were experimentally tested using a functional 
cAMP assay were chosen from a list of compounds that had been identified through a combined 
ligand and structure based virtual screening approach (Evenseth et al. 2018, unpublished work). 
The ligand based section was based on the structure of 55 known GABAB receptor ligands, 42 
agonists and 13 antagonists, that were clustered to separate agonists from antagonists, giving a 
total of 6 clusters after manual modification. Pharmacophores were created based on these 
clusters, but only one pharmacophore per cluster was validated as of sufficient quality. The 
validated pharmacophore models were used to screen a compound database of five million 
compounds, the hits from this screening were then docked into the VFT domain of the GABAB 
receptor. Their MM-GBSA scores were calculated and a selection of the compounds was 
brought forwards to the in vitro testing stage. The first initial screening to be performed on a 
selection of these compounds was carried out as part of the present project. 
As this was an initial assay screening that was not performed in a triplicate of assays, the current 
results might be affected by experimental errors. However, the assay results may still serve as 
an indication of the test compounds’ properties. With the study of these compounds still being 
ongoing and the work related to them unpublished, the compounds themselves are not the focus 
of this portion of the project, rather the focus is on the methods used to test the compounds and 
also on the experimental errors that may affect the results of the assay.  
Different factors during the functional assay may contribute to the deviation of assay results. 
The following analysis will therefore focus on the major factors. The first part of the assay 
procedure where error can be introduced is contamination during the cell culture stage. This 
could be bacterial or fungal, especially the WT cell line that used culture medium without 
adding antibiotics. The GABAB cell lines medium does contain antibiotics ensures that the cells 
continue to actively express the GABAB receptor, it also protects the cells to a certain degree 
from bacterial contamination. Both cell lines are however highly vulnerable to fungal 
contamination and proper sterilization and care during the cell growth stages are therefore 
crucial.  
Other issues can be using PBS or culture medium that is too old. Both can have adverse effects 
on the cells and thereby potentially affect the cell behavior during the assay. During the cell 
growth and harvesting stages, cell quality can be affected by leaving cells in AssayComplete™ 
Cell Detachment Reagent for longer than 2 minutes. Although the exact mechanism is 
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unknown, the unstable results and reduced GABAB receptor activity were observed from an 
earlier experiment. Since ethanol can inhibit forskolin-activated adenylate cyclase (122), 
ethanol contamination during the cell harvesting stage can therefore create a false agonist like 
activity in the assay results or reduced forskolin stimulation. Cell aggregation in the cell 
suspension is the major problem causing incorrect cell counting. After centrifugation, when the 
cell pellet is not resuspended properly, the counted cell number could be lower than what it 
should be. Even worse is, the aggregated cells could resuspend into the cell suspension during 
the dilution step, and therefore result in the calculated cell concentration being lower than the 
actual assay cell concentration. If the assay is to be repeated multiple times, then the cell 
concentration deviation between assay repetitions could cause deviation in the final assay 
result. This would affect the repeatability of the assay. 
The second part of the assay procedure where error can be introduced has to do with the mixing 
of buffers, stock solutions, the addition of compounds, essentially anything requiring 
measurements and/or pipetting. Human error and errors introduced by assay equipment, such 
as a not properly calibrated pipette are also important factors. The volume being pipetted by a 
pipette is very accurate if it has been properly calibrated, but it is not 100% precise. Following 
procedure can improve the pipetting accuracy: precalibrate the pipette, avoiding bubbles, 
wetting the inside wall of pipette before pipetting larger volumes, change the tip during serial 
dilution of GABA and also checking for liquid stuck on the outside of the pipette. When making 
stock solutions and serial dilution it is also better to pipette larger volumes. If a mixture requires 
a 9:1 ratio, then mixing 90µl+10µl provides a larger room for error than if 900µl+100µl was 
pipetted. 
In the creation of stock solutions and assay buffers there is also a need to weigh the various 
compounds that are to be dissolved. A mistake here, for instance having some of the compound 
end up on the scale instead of in the measurement container, would introduce incorrect solute 
concentration. With a test compound this can cause a wrong concentration being used in every 
assay. If however the mistake is with one of the components of the assay buffer, such as calcium 
concentration which is known to affect GABAB receptor activity, this will then affect the 
measured test compound activity also (123, 124). Therefore, prioritizing caution and patience 
in these steps can introduce lower errors. Ensure the scales are clean, be careful not to spill any 
of the compounds/assay buffer components outside their measurement containers. When 
dealing with powders be aware of static. If the compound is somehow contaminated it is better 
to throw it away and try again. 
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For the assay that was performed with the 10mM stock compounds solution, there were several 
time points when error may have been introduced when pipetting. These were when mixing 
the previously frozen stock solutions of test compounds in preparation for the assay, the volume 
to be pipetted was only 6 µl, which went into 994 µl of the appropriate buffer. Even a small 
deviation in volume for the test compound would have affected the final concentration of the 
compound used in the assay quite significantly. There was also room for error when creating 
the forskolin stock in a 1:1 mix, it is better to use the same stock forskolin solution for each 
test compound. Different concentrations of forskolin can result in different maximum cAMP 
formation in the assay. This can be easily observed from the results of the forskolin control 
(Figure 22). The difference of forskolin in the controls in Figure 22 could be caused by 
pipetting error of forskolin stock into the 5G control. A visual inspection of the leftovers in the 
compound preparation tube confirmed this on the day of the assay. For the GABAB cells there 
was also the additional issue of adding GABA into forskolin and test compound mixture. The 
additional pipetting leaves room for more potential errors. Then there is the cell numbers, 
which are affected by pipetting even after cell counts have been correctly performed. 
Immediately after the cells have been diluted to the appropriate concentration of 0.5 million 
cells/ml, cells were incubated for 1-hour incubation (Figure 7) at 18°C. At this stage there is 
also the ever-present risk of pipetting the wrong volume. Since cells rapidly sink towards the 
bottom of the tray they are being pipetted from, it is therefore necessary to perform a quick 
premix (such as shaking the tray or pipetting up and down two times) of the cell suspension 
before transferring diluted cells into the incubation tubes. If the cells are allowed to sink to the 
bottom of the tray without being mixed again before the next round of pipetting, then there 
would be a higher cell concentration at the bottom of the solution in the tray than near the top.  
The main issue with pipetting at the final stages of the assay is that the pipetting must happen 
quickly because the reaction begins immediately upon the liquids mixing, a difficult task 
complicated further by the entire procedure being performed in the dark because of the reagents 
being light sensitive. The issue of quickly pipetting can be solved in part through the use of 
Eppendorf Multipette M4, a positive displacement high precision pipette. This pipette is 
especially suitable to viscous or volatile liquids, such as the antibody solution in our assay. In 
addition, it is important to carefully pre-plan where to pipette each of the reagents, in a manner 
where the tip of the pipette would not be contaminated by droplets from the pipetting of 
previous reagents or cell-compound mixture in the incubation tube. During the assay this was 
solved with pipetting the compounds against the wall of the wells at different heights and sides, 
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starting at a low angle and working upwards. Fast and accurate pipetting in the dark raised an 
additional challenge during the assay. With proper planning it is possible to determine how 
many wells can be completed with a Multipette M4 pipette for each of the reagents. The 
darkness can make it difficult to determine if there is any liquid inside the pipette tip, a potential 
solution here is to carefully check the reagent inside the tips, as much as the low light conditions 
allow.  
Light exposure is the last factor that could introduce experimental error. As the reagents used 
to measure the cAMP levels are light sensitive, exposure to light will severely affect the results 
of the assay. Which is why after adding the final reagent, Solution A, it is a good precaution to 
cover the entire assay setup (Figure 7) in aluminum foil to prevent light exposure during the 
12-14 hour long incubation. The next stage where there is a danger of light exposure is when 
the transfer from the assay setup to the clear bottom 384-well assay plate is occurring. Light 
exposure at this stage can come from many sources, the best option to avoid it is to minimize 
the opportunity for unexpected light to occur. During transport to the ClarioStar® plate reader 
for the luminescence readout the plate should be covered in aluminum foil. Before the assay 
plate is put into the plate reader, turn off the light in the room where the plate reader is located.  
During the performance of the assays for the project, there were two particularly notable things 
that were done to minimize the chance of assay failure. The first is to perform the assay at 18°C 
to slow the reactions occurring within the incubation tubes. This slight reduction in temperature 
prolongs the reaction time, and therefore gives more time to add both test compounds and 
reagents without adversely affecting the results of the assay. Submerging incubation tubes in 
pre-cooled water baths ensures that each assay is carried out at the same temperature. An assay 
carried out at room temperature during winter may be carried out at 19°C, while a follow-up 
assay that is carried out during the summer might have a temperature of 25°C. Earlier 
experiments showed that forskolin stimulated cAMP formation in our GABAB cells reached 
maximum level at a lower speed at lower temperature (data not shown). The significant degree 
of temperature variation would affect the cell reactivity and could lead to the assay results 
showing significant divergence from one another. Keeping a constant temperature for assays 
is a good step to minimize the variation between assays. 
The second notable thing is related to ensuring sufficient cells for performing the assay. The 
initial cell culture harvests that were carried out tended to have a somewhat low cell counts 
considering the quantity of cells that should have been in a T75 flask at ~70% confluency. The 
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difference in total cell count can be seen quite clearly on Figure 22 and Figure 23. The WT 
assay which was performed first had roughly 2.93 million cells after the harvesting was 
complete, while the GABAB cells had 6 million cells. This was not the first cell harvesting, as 
there had been done several times prior to the assay as practice and the results from those trial 
runs were fairly consistent with that of the WT assay. There are numerous other factors that 
may have contributed to this sizable difference and the benefit of washing four times has been 
proven to give better assay results, perhaps due to reducing the nonspecific binding of GABA 
to leftover culture medium components. 
The purpose of this part of the project was to gain a greater understanding of the laboratory 
work, experimental techniques and problem solving in a laboratory environment. The second 
purpose was the results of the assay, gain an indication of the test compounds status as a 
GABAB receptor antagonist. The results of the assay did give an indication that several of the 
compounds may act as GABAB receptor agonists, but further multiple repeats of the initial 
screening assay as well as the effect of selected potential hit compounds on GABA dose-
response are required to confirm and characterize any hit compounds. The ones that are 
confirmed to affect the GABAB receptor would then have to be tested at multiple 















The recently rendered X-ray crystal structure of SERT was used for a computational study 
investigating the central and allosteric binding sites of SERT. Emphasis was placed on which 
amino acids most heavily interacted with the ligands and differences between the results of the 
MD simulation and docking study of experimentally verified SERT inhibitors was explored. 
Each simulation identified key amino acids between each respective ligand and binding site. 
For the central site simulation it was seen that both (S)-citalopram and serotonin had very 
strong interactions with TYR95, and serotonin having more numerous strong interactions than 
(S)-citalopram. For the allosteric site simulations they identified PHE335 and GLU494 as the 
strongest interacting partners for (S)-citalopram and serotonin respectively. The interactions 
between the ligands and the allosteric site were also not as strong overall as the interactions of 
the central site. From the combined data of the MD simulations and the docking study 
numerous amino acids were identified as potential targets of a mutation mapping study looking 
at effects on SERT activity. Most of the amino acids that were of interest for such as study 
were located in the allosteric site (ARG104, ASP328, ALA331, GLU493, GlU494, GLY498, 
PRO499, LEU502 ILE552 and PHE556), as the central site has been partially investigated 
though such methods in the past. The MD simulation also found that (S)-citalopram and 
serotonin each had a favored interaction type regardless of binding site, hydrophobic 
interactions for (S)-citalopram and H-bonds for serotonin. Serotonin was also observed to 
maintain more interactions on average throughout the simulation than (S)-citalopram did, 
regardless of binding site. The experimental portion of the study successfully carried out an 
initial screening of ten compounds identified as potential GABAB receptor antagonists. None 
of the tested compounds showed any significant indications of antagonistic effect on the 
GABAB receptor, but three of the compounds did show indications of being GABAB receptor 
agonists. The compounds identified as potentially being agonists require further assays to 
confirm that their perceived activity was not caused by experimental error. The experimental 
portion of the study also provided experience working in a laboratory environment and 
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8.1 Induced Fit Docking 
Appendix Table 1: The table below show additional information regarding the experimentally 
verified (100) compounds that were selected for the in silico docking study. The ID refers to 
the compounds ID number, which is used to keep the compounds organized and sorted. The 
Compound Name refers to the name of the compounds in their respective vendor database, 
Vendor refers to the company that the compound was acquired from. Cluster refers to what 
cluster the compound was placed in during the virtual screening process before it was 
experimentally tested. Path refers to the method by which the compound was discovered to 
possibly be an inhibitory compound of SERT before the experimental verification. Ki [nM] ± 
SEM is the necessary Ki in nM for the compound to exhibit an optimal inhibitory effect, the 
standard error of mean is also listed. The % is the percent of inhibition the compound was 
found to provide during in vitro testing with the optimal concentration of the inhibitory 
compound in a competitive binding assay with [3H]-citalopram. 
ID Compound Name Vendor Cluster Path Ki [nM] ± SEM % 
1 ASN13153175 AS C01 H2L 90.5 ± 8.7 69 
2 T5544147 EN C02 VS 336 ± 41.5 46 
3 5417988 CB C03 H2L 926 ± 57 33 
4 T6125232 EN C04 H2L 1.5 ± 0.3 54 
5 46524932 CB C05 VS 152 ± 12.7 72 
6 9029307 CB C06 VS 42.5 ± 1.3 49 
7 9066608 CB C06 VS 28.4 ± 0.3 30 
8 5458751 CB C07 VS 50 ± 1.7 52 
9 BAS12193322 AS C08 H2L 22.3 ± 2.8 35 
10 C466-0145 CD C09 VS 86.1 ± 8.1 63 
11 T6406455 EN C10 H2L 127 ± 4.5 30 
12 T5777260 EN C10 H2L 129 ± 9.8 47 
13 T6574432 EN C11 VS 56 ± 8.2 45 
14 T0502-9459 EN C12 VS 268 ± 16 40 














Appendix Figure 1: The figure displays the interactions the docked ligands had with the amino 
acids of the central site. The number in the left corner of each interaction diagram (1-4) is the 





Appendix Figure 2: The figure displays the interactions the docked ligands had with the amino 
acids of the central site. The number in the left corner of each interaction diagram (5-8) is the 





Appendix Figure 3: The figure displays the interactions the docked ligands had with the amino 
acids of the central site. The number in the left corner of each interaction diagram (9-12) is the 





Appendix Figure 4: The figure displays the interactions the docked ligands had with the amino 
acids of the central site. The number in the left corner of each interaction diagram (13-16) is 







Appendix Figure 5: The figure displays the interactions the docked ligands had with the amino 
acids of the allosteric site. The number in the left corner of each interaction diagram (1-4) is 





Appendix Figure 6: The figure displays the interactions the docked ligands had with the amino 
acids of the allosteric site. The number in the left corner of each interaction diagram (5-8) is 





Appendix Figure 7: The figure displays the interactions the docked ligands had with the amino 
acids of the allosteric site. The number in the left corner of each interaction diagram (9-10) is 





Appendix Figure 8: The figure displays the interactions the docked ligands had with the amino 
acids of the allosteric site. The number in the left corner of each interaction diagram (13-16) 
is the ID of the ligand (See Appendix Table 1). 
